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The majority of diseases are caused or influenced by hereditary factors. Most of the 
rare disorders, which are often devastating and sometimes even life-threatening, 
are monogenetic disorders caused by rare genetic changes (mutations). In contrast, 
complex diseases, which are often chronic diseases or diseases of the elderly, are 
caused by the interplay between rather common genetic variants and environmental 
factors. To understand, predict and possibly cure hereditary diseases, recognition 
of the causal genetic factors is crucial. The main strategy that is followed in the 
discovery of causative variants for both rare and common diseases, is to first 
identify candidate loci (i.e. a region in genome either associated or linked to the 
disease under study and containing one or more genes), then fine-mapping of the 
region (to refine the region to preferably a single gene), followed by investigation of 
the refined candidate locus for causative mutations by direct re-sequencing. When 
we look at the progress made in disease gene mapping from 1997 onwards (Figure 
1), we can see a fairly steady and high discovery rate in the field of rare disorders. 
Figure 1 Approximate number of mapped loci from 1997 till 2011 for Mendelian and complex diseases.
However, success in mapping complex traits was lagging behind, mainly due to the 
methods available. Linkage studies, for example, have proved extremely powerful 
for the mapping of monogenetic disorders, but have hardly contributed to the 
discovery of common loci. The field of complex disease genetics changed entirely in 
2005 with the introduction of the Common Disease-Common Variant hypothesis and 
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the availability of new tools to test it. At that time the Human Genome Project had 
delivered a Human Catalogue of Common Variants and inspired the development 
of array technology to include these variants on a chip for large-scale genome-wide 
genotyping. This laid the foundation for association studies in complex traits. Since 
the first genome-wide association study (GWAS) in 2006, thousands of loci have 
been correlated with hundreds of complex traits.
For many years fine-mapping of the candidate loci was an absolute necessity before 
embarking on the re-sequencing of single genes due to the lack of affordable and 
high-throughput methods. Again, it was a technological breakthrough that changed 
the field of gene mapping. In 2009 next generation sequencing technology was 
launched, a revolutionary method whereby resequencing of the entire human 
genome could be done within a week compared to the 13 years it took to complete 
the Human Genome Project. At the same time, the cost had also dropped from 
$3 billion to approximately $15,000 per genome. Next generation sequencing 
quickly became an attractive tool for investigating candidate regions, as well as for 
sequencing all the genes in the genome and solving a disease without previous 
mapping information (i.e. exome sequencing). To date, many rare, monogenetic 
disorders (recessive and dominant), as well as a limited number of complex diseases, 
have been resolved using this approach.
The aim of this thesis was to use different state-of-the art approaches for fine-
mapping and discovering new genetic variants causing both monogenetic and 
complex diseases.
In chapter 1, I briefly present the history of genetic mapping and explain the 
differences between rare and complex diseases with respect to the genetic and 
environmental factors as well as the nature of the variants. I further describe 
methods used for mapping candidate regions in complex and rare disorders and 
factors that could influence the replication phase. Finally I explain the powerful 
tool of next generation sequencing and its possible applications in discovering new 
variants and fine-mapping candidate regions. 
In chapter 2, “Functional characterization of mutations in the myosin Vb gene 
associated with microvillus inclusion disease”, I present the wide spectrum of 
mutations in the myosin Vb gene that lead to microvillus inclusion disease (MVID). In 
this study I show three families of different ethnic origins in which the same disease 
is caused by different mutations in the same gene (i.e. allelic heterogeneity). I also 
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demonstrate the power of combining homozygosity mapping with the knowledge 
of the protein product in uncovering the candidate gene.
In chapter 3, “True autosomal dominant inheritance of FMF caused by a mutation in 
exon 8 of the MEFV gene”, I present an exome-wide sequencing study as a mutation 
mapping tool for this dominant autosomal, periodic fever syndrome. By sequencing 
two affected, related individuals and applying a “step-wise” filtering approach, 
I was able to map the causative mutation to the 577 codon in the MVEF gene. This 
work clearly shows the power and high sensitivity of next generation sequencing in 
looking for causative mutations in monogenic diseases. 
Chapter 4, “Exome sequencing in a family segregating for celiac disease”, presents 
the use of next generation sequencing for fine mapping linkage regions in a four-
generation family segregating for celiac disease. This complex disease presented in 
a dominant-like manner. As we were not able to find a likely candidate variant in any 
of the linkage regions, we also investigated the entire exome for nonsense variants 
that could explain the heritability of the disease in this family. Although we were 
not able to identify a mutation, we pinpointed the different aspects and bottlenecks 
that show how difficult it is to solve a complex disease in familial studies. 
In chapter 5, “Functional polymorphism in IL12B promoter site is associated with 
ulcerative colitis”, I show the correlation of genetic variants in the IL12b gene to 
ulcerative colitis, one of the subtypes of Inflammatory Bowel Disease, which is a 
complex immune-mediated disease. This study presents a way of mapping causative 
variants by the “cross-disease” replication of a variant in a gene that has already 
been associated to another immune-mediated disease. 
In chapter 6, “Cross-ethnic replication and fine-mapping of celiac disease loci in a 
north Indian population”, we performed a cross-ethnic replication study in a north 
Indian population of 26 loci previously associated to celiac disease in Europeans. 
To correct for the high allelic heterogeneity caused by differences in linkage 
disequilibrium structure between Europeans and Indians, we used two replication 
methods and successfully replicated 50% of the association. Furthermore, we were 
able to narrow down the association signal using an innovative Cross test statistic to 
check for risk haplotypes at the IL2-IL21 locus, since the same risk haplotype in Indians 
was shorter due to the smaller linkage disequilibrium intervals in that population.
In chapter 7, I summarize all the work I have done and discuss the future perspectives 
for the mapping of causative variants in monogenic and complex diseases.




CD-CV Common disease-common variant 
CD-RV Common disease-rare variant
CeD Celiac disease 
cM Centimorgan
CNV Copy number variation
dbSNP The Single Nucleotide Polymorphism Database
DNA Deoxyribonucleic acid
ESP Exome sequencing project
FMF Familial Mediterranean fever
GIH Gujarati Indians in Houston
GoNL Genome of the Netherlands project 
GWAS Genome-wide association study 
HapMap Haplotype map of human genome
HLA Human leucocyte antigen 
IBD Innflamatory bowel disease 




LD Linkage disaquilibrium 
LOD Logarithm of the odds
MAF Minor allele frequency 
Mb Megabase
MDS Multi-dimensional scaling analysis
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MEFV Mediterranean fever gene
MVID Microvillus inclusion disease 
MYO5b Myosin V b gene
NGS Next generation sequencing 
NPL Non-parametrical linkage values
OMIM Online Mendelian Inheritance in Man 
OR Odds ratio
PBMC Peripheral-blood mononuclear cells
PCR Polymerase chain reaction
qRT-PCR Quantative real-time polymerase chain reaction
RNA Ribonucleic acid
SNP Single nucleotide polymorphism 
SV Sequence variant
UC Ulcerative colitis 
UTR Untranslated region 
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Mendelian vs. complex disorders
There are about 25,000 protein-coding genes in the human 
genome and any alteration in these genes can potentially lead to a 
genetic disorder. The main concept underlying a genetic disorder is 
that of inheritance; the disease may affect other people related to the 
proband and it will co-segregate in families. One of the first genetic 
diseases to be recognized was reported in the 2nd century by Rabbi 
Simon and Gamaliel. They described a family in which an infant and its 
three maternal cousins had died from extensive bleeding after medical 
procedures; this disorder is now known as hemophilia and it is caused 
by mutations (alterations) in genes regulating the blood coagulation (1). 
Some genetic disorders are strongly determined by genes, 
these are called monogenic or Mendelian disorders, while many 
other disorders result from multiple genes interacting with environ-
mental factors (called multifactorial or complex disorders). Thus, we 
can place each disease at a different point along a continuous spec-
trum, depending on whether the genetic or environmental effect is 
the strongest determining factor. The majority of infectious diseases 
are triggered by environmental factors so these lie at one extreme of 
the spectrum (Figure 1). Mendelian diseases, such as cystic fibrosis, lie 
at the other extreme and are mainly determined by mutations in the 
genome. Complex disorders lie in the middle of the spectrum as they 
are strongly influenced by both types of factors (Figure 1). 
Figure 1 The continuous spectrum of disease causation. Mendelian diseases, like cys-
tic fibrosis or microvillus inclusion disease (MVID), are caused by strong genetic fac-
tors, whereas other disorders are similar to infectious diseases and are mainly caused 
by environmental factors. Complex disorders lie in the middle of the spectrum and are 
due to environmental and genetic factors interacting and playing an important role in 
the pathogenesis. 
Proband: is the first af-
fected family member 
who seeks medical at-
tention and was diag-
nosed with a genetic 
disorder.
Co-segregation: is a 
segregation pattern 
that shows how often 
the variant coincides 
with the disorder in 
the pedigree.
Mutation: is an altera-
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Monogenic disorders are rare, and caused by mutations of a 
large effect size in one gene (Figure 2). These mutations result in very 
low minor allele frequencies (MAF) of the mutant alleles (MAF<1%). 
The mutations often occur in highly conserved regions that are 
prone to negative evolutionary selection (2, 3). Around 60% of the 
genetic mutations leading to monogenic disorders have a missense or 
nonsense character, around 10% are splice sites, 7% are insertions/
deletions (indels) and less than 1% occur in regulatory regions (4). 
Figure 2  There is a wide range of variants with different effect sizes (OR, odds ratio) 
and minor allele frequencies (MAF). Mendelian diseases are caused by rare variants 
with very low MAF and a high OR; they can be successfully identified by linkage or 
homozygosity mapping, for example. Common variants with high MAF and a low OR 
are often associated to complex diseases. Low frequency variants of intermediate 
effect size are an unexplored group as they are not detectable with linkage or genome-
wide association studies (GWAS). One way to investigate their involvement in genetic 
disease is to sequence the entire genome, which has become feasible with next-
generation sequencing technology. 
Effect size: the strength 
of relation between 
variant and the trait. 
Minor-allele frequency 
(MAF): the frequency 
of the allele that is less 
often observed in a 
general population. 
Conserved regions: are 
crucial and function-
ally important regions 
in DNA that do not al-
low variation by strong 
negative selection. 
Missense mutation: is 
a change in the base 
sequence of a gene 
that alters or elimi-
nates a protein. 
Nonsense mutation: is 
when codon is changed 
to a stop codon, result-
ing in a truncated pro-
tein product. 
Splice site mutation: 
is when alternation is 
location in the DNA 
sequence involved in 
removing the noncod-
ing areas to form a con-
tinuous gene transcript 
for translation into a 
protein (so called splic-
ing).
Indels: are defined 
as either an insertion 
or deletion. Insertion 
involves the addition 
of genetic material 
whereas deletion lack 
of the genetic material. 
Odds ratio (OR): is a 
statistical measure of 
effect size reflecting 
the effect of the muta-
tion on the disease 
Linkage or homozygo-
sity mapping: are fami-
ly-based methods used 
to find the region in a 
genome carrying the 
causative gene. Widely 
used for mapping mo-
nogenic disorders.
Genome-wide asso-
ciation study (GWAS): 
is population-based 
method (case-control) 
for mapping regions 
associated to a disease. 
Eﬀect size (Odds ratio) 
Minor allele frequency (MAF) 
High OR > 3 
Intermediate
1.5 < OR < 3
Low 
1.0 < OR < 1.5 








Low frequency variants 
of small eﬀect size
Group of variants being 
poorly explored 
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Gregor Mendel was, in 1866, one of the first to outline the 
inheritance of monogenic traits in pea plants, and he described 
recessive and dominant models. In 1902, Garrod showed that 
alkaptonuria (black urine disease) was inherited recessively, so that the 
“inborn errors of metabolism” were present in the proband’s siblings 
but not in the parents (5). The inheritance of monogenic disorders has 
been well established and follows six main patterns: 
1) Autosomal dominant: where the presence of one mutated allele 
on an autosome is enough to cause the disease, 
2) Autosomal recessive: where the presence of two mutated alleles 
in the same gene on two homologous autosomes leads to disease, 
3) X-linked recessive: where the presence of two mutated alleles on 
the X chromosome (in females) or one (in males) are needed to 
cause disease, 
4) X-linked dominant: where the presence of one mutated allele on 
the X chromosome is enough to cause disease, 
5) Y-linked: where the presence of one mutated allele on the Y 
chromosome is needed to cause disease,
6) Mitochondrial-linked: where maternal mitochondrial DNA carries 
the mutation causing the disease. This is not typical Mendelian 
inheritance, as none of the parental DNA is inherited, however, 
these disorders are also monogenic.
Complex diseases are fairly common in the general population. 
For example, the prevalence of celiac disease, a complex, immune-
related intolerance to gluten, is around 1% in Caucasian populations (6). 
The first hypothesis on the character of causative variants for complex 
diseases was based on their high prevalence in the population, and 
was called the “common disease-common variant” (CD-CV) hypothesis 
(Figure 3). It states that complex diseases are caused by a combination 
of multiple common polymorphisms, with MAF > 5%, of small effect 
Dominant: alleles that 
determine the pheno-
type displayed in a het-
erozygote with another 
(recessive) allele. 
Recessive: is a gene 
that is phenotypically 
manifest in the ho-
mozygous state but is 
masked in the pres-
ence of a dominant al-
lele.
Allele: is an alternative 
form of a gene; any one 
of several mutational 
forms of a gene.
Autosome: is a nuclear 
chromosome other 
than the X- and Y-chro-
mosomes. 
Mitochondrial DNA: 
is a mitochondrial ge-
nome consists of a cir-
cular DNA duplex, with 
5 to 10 copies per orga-
nelle. 
Celiac disease (CeD): 
is an complex disease 
with very strong im-
mune respond, in small 
intestine, to the gluten 
proteins.
Polymorphism: is a 
change in the genomic 
DNA and it differs from 
a reference sequence. 
Widely used for map-
ping complex traits.
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size, with each polymorphism explaining a small part of the heritability 
(Figure 2) (7, 8). In total, from 2005 to 2010, some 5,854 common 
genetic single nucleotide polymorphisms (SNPs) were found to be 
associated with 540 complex disorders (9). Celiac disease is currently 
associated with 57 non-HLA SNPs representing 39 loci, and although 
no causative gene was found, the majority of these SNPs map close to 
immune-related genes, explaining some 15% of the heritability (10). 
The work of Thomas and Kejariwal showed that the majority of coding 
variants associated through GWAS studies with complex diseases 
map to less conserved regions than the severe mutations found for 
Mendelian diseases, which may explain their more moderate effect 
size (3).
A second hypothesis, “common disease-rare variant” (CD-
RV), states that complex genetic diseases could be due to variants 
of low MAF (< 5%), and moderate effect size (8) (Figure 2), with an 
incomplete penetrance in some families (11). The CD-RV hypothesis 
could explain part of the “hidden heritability” of complex disorders. 
Moderate and rare variants have so far remained largely undiscovered, 
as the DNA chips used for genome-wide association studies (GWAS) do 
not contain variants with a MAF < 5% (8, 12). These variants could be 
present within the GWAS loci and collectively drive the association to 
the disease (“synthetic association”) (13, 14) (Figure 3). For example, 
several rare variants in the NOD2 gene are strongly associated with 
inflammatory bowel disease (IBD) and although the variants show 
a familial clustering they do not follow a clear inheritance pattern 
(11). The work of Cohen et al. in 2004 and 2005 showed that extreme 
phenotypes of metabolic traits are also strongly correlated with rare 
variants in metabolic candidate genes (15, 16). The CD-RV hypothesis 
is very likely to hold true for the majority of familial, Mendelian-like 
subtypes of complex disorders. For example, a mutation in the VPS35 
gene has been identified in a large Austrian family segregating for 
Familial Parkinson’s disease (17), and recent case-control studies on 
hyperglycemia, IBD and gout have shown an excess of rare variants in 
loci mapped by GWAS (18-20). 
Single Nucleotide Pol-
ymorphism (SNP): is a 
DNA sequence varia-
tions that occur when a 
single nucleotide (A, T, 
C, or G) in the genome 
sequence is altered. 
Heritability: the pro-
portion of the phe-
notypic variation in a 
trait that is due only 
to the genetic set up. 
It is measure as the 
correlation of traits 
between related indi-
viduals. The part of the 
heritability that cannot 
be explained with ge-
nome-wide association 
studies for complex 
diseases is called hid-
den heritability.
Coding variants: are 
changes in the part of 
the genome coding for 
proteins.
Penetrance: is the 
probability of the 
genetic trait to be 
expressed. 
Synthetic association 
hypothesis: is one of 
the explanations for 
hidden heritability of 
complex diseases. It 
claims that cluster of 
low-frequency variants 
drive the association 
of common loci in GWA 
studies. 
Inflammatory bowel 
disease (IBD): is an 
autoimmune, complex 
disorder affecting 
either the small 
intestine (ulcerative 




is a population study 
where the hypothesis 
is tested by comparing 
occurrence of the 
object (e.g. frequency 
of an allele) between 
cases (diseased sub-
jects) and controls (non- 
diseased subjects). 
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Figure 3 Illustration presents genealogical tree showing rising of the tagging 
( ) and causative variants ( ). Panel A represents common disease-
common variant (CD-CV) theory where the best tagging variant ( ) captures the 
causative common varinat ( ). Panel B represents “synthetic association” hypothesis 
where the best tagging SNP ( ) captures the combined effect of many causal rare vari-
ants ( ). Figure adapted with permission from Wang et al., 2010 (39).
In summary, the current data suggests that both hypotheses, 
CD-CV and CD-RV, may hold true and help explain the genetic 
architecture of complex diseases, since there is a wide genetic 
heterogeneity within the variants so far associated to complex diseases 
with regard to their effect size and frequency. The fractions of common 
and rare variants explaining the heritability of complex disorders will 
also vary for each disease (12, 21).
Hunting for the causative genes 
To understand and treat genetic disorders, it is essential to 
identify the causal gene or variant. In general, there are two ways 
of looking for the causal gene: using a hypothesis-driven (a) or a 
hypothesis-free approach (b). In a genome-wide approach, we do not 
apply any hypothesis for searching for certain candidate genes or loci 
(22). In a hypothesis-driven approach, on the other hand, the candidate 
gene is investigated based on known, underlying disease mechanisms, 





A. Canonical assumption 





B. Synthetic association 
(MAF of tagging SNP > MAF of causative variants)
The best tagging common variant
Other common variant
Causative variants
Legend to the ﬁgure
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(a) Hypothesis-driven approaches
 In hypothesis-driven approaches, knowledge of underlying 
mechanisms of the disease suggests protein products for possible 
involvement in the disease pathogenesis (“reverse genetics”). 
For example, Sato et al. (2007) showed that Rab-8-deficient mice 
expressed a reduced amount of the RAB8 protein, identical to what 
was observed in a patient with microvillus inclusion disease (MVID) 
(24). Although Rab8 turned out not to be the causative gene for MVID, 
this experiment still suggested further candidate genes for screening 
and led to the discovery of MYO5b as the causal gene that interacts 
with RAB8 in the same pathway (25, 26). Using reverse genetics 
without mapping the candidate locus has severe limitations, especially 
in identifying genes for complex disorders, since these can have a 
broad phenotypic spectrum and thus an unclear disease mechanism. 
A candidate approach is therefore most effective when applied to a 
previously mapped locus (so-called “positional candidate mapping”). 
(b) Hypothesis-free approach 
 The hypothesis-free approach can be divided into two phases: 
first a genome-wide scan, in which appropriate statistical measures are 
applied to determine any significant association between the gene’s 
position in the genome and the disease (by either linkage analysis, 
homozygosity mapping, or a genome-wide association study), or by 
sequencing the entire genome for variants matching the disease criteria 
(whole genome re-sequencing). The second phase is replication, where 
the region, locus or variant is investigated in an independent study 
designed to confirm the preliminary findings. 
Genome-wide mapping phase
 Genome-wide linkage scans These are mainly used to map 
candidate loci in families segregating for disease, by finding signifi-
cant linkage between a marker (for example, a SNP or microsatellite) 
and the disease in the pedigree (family-based), while taking sequence 
variants (SVs) into account. There are two types of linkage analysis: 
Locus: is the physical 
place in the DNA 
sequence measured in 
base-pairs (bp). 
Microsatellite: also 
called short tandem re-
peats, are highly poly-
morphic sequences 
used for the genetic 
mapping.
Sequence variant (SV): 
is a change in the 
genomic DNA found by 
re-sequencing meth-
ods that differs from a 
reference sequence. 
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first, model-based linkage (parametrical) in which a Mendelian model 
of inheritance is assumed for analyzing the co-segregation. This model 
can be recessive or dominant. In principle, co-segregation decreases 
if two loci are far away from each other, so that recombination takes 
place more frequently (27). The significance of parametrical linkage is 
reported as a logarithm of the odds (LOD) score; this is a function of 
recombination for each genotyped locus (or loci) at the disease locus. 
The larger the LOD score, the stronger the evidence for linkage with 
the disease, but a negative LOD score means there is no co-segregation 
present. This approach was successfully used in mapping Mendelian 
candidate loci with a strong genotype-phenotype correlation. 
The second type of linkage analysis is non-parametrical linkage 
in which no model assumptions are made. This type of linkage is used 
in complex diseases, since there is often an incomplete penetrance. 
The analysis is performed in only the affected individuals from the 
family (“affected only”); the linkage is based on the sharing of alleles, 
identical-by-descent, at the disease locus. Both parametrical and 
model-free approaches have been used in mapping the candidate 
regions in large families that segregate for a complex disease (28, 29). 
Before the GWAS era (i.e. pre-2005), the most widely used method for 
mapping complex disorders was a linkage-based analysis in sib-pairs, 
where both first-degree relatives are affected (27, 30). There is 0.25 
probability of no identity-by-descent sharing, 0.5 probability for one 
allele to be shared, and 0.25 for two alleles to be shared as identity-
by-descent. A linkage approach would be adopted if both sibs share 
more identity-by-descent than would be expected by chance. Such 
an approach was used to map a candidate locus on chromosome 19 
linked to celiac disease (31). 
 Genome-wide homozygosity mapping This approach is used to 
study rare, autosomal recessive diseases by finding large, homozygous 
regions spanning the causative mutation in consanguineous families 
and in inbred populations (32). In recessive diseases, the children of 
related parents (for example, parents who are first cousins), often 
carry the causative mutation within large, homozygous-by-descent loci 
Recombination: is the 
exchange of DNA frag-
ments during meiosis.
Identical-by-descent: 
is when the inheritance 
of allele at locus can be 
established vertically 
whereas identical-by-
state (IBS) is when the 
alleles are the same 






lies: where the parents 
in a family are blood 
relations (inbreeding) 
often first cousins. 
Populations with a high 
degree of consanguin-
ity are called inbred 
populations.
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(autozygosity). In complete pedigrees, we can apply the same statistical 
techniques as for parametrical linkage and the LOD score will indicate 
whether the linkage is significant (32). An alternative approach is to 
genotype affected siblings from the family and to look for the largest 
homozygosity region, as it has been shown that causative mutations 
often map to one of the larger homozygous regions (26, 33).
 Genome-wide association studies (GWAS) These studies are 
used to investigate complex traits by finding associations between 
SNPs and the disease, mostly by using a case-control design. In GWAS, 
the significance of the differences in allele frequencies of genotyped 
markers is established in controls (unaffected individuals) versus cases 
(affected individuals) (34, 35). Markers used for association studies 
are selected from common SNPs in HapMap, which is an international 
catalogue of genetic variants in humans (36). Hence, GWAS can be 
used to test the CV-CD hypothesis for any complex disease (22). Due 
to the small effect size of the individual risk variants (OR < 1.5), a high 
number of associated loci explain only a small part of the heritability 
(see Figure 2). For example, around 71 loci have been associated with 
Crohn’s disease (a subtype of inflammatory bowel disease), but explain 
only 20% of the heritable risk (37). A standard GWAS is an indirect 
mapping approach where an associated, common SNP (MAF > 5%) 
is tagging (tagging SNP) the unknown, causal variant. This is possible 
since variants are in linkage disequilibrium (LD), which means they 
are inter-dependent, create haplotypes, and are inherited together. 
Thus, a genotyped SNP can predict and ‘tag’ other variants that have 
not been genotyped (34, 38). As a GWAS can identify loci rather than 
single genes, further fine-mapping of the associated loci is required to 
find the true causal gene or variant (39). There are two hypotheses on 
the character of causative, tagged variants: one is that the common 
SNP is tagging the other common causative variant of small effect 
(CD-CV hypothesis), when a causal mutation arose together with the 
common tagging SNP; the other is where the common SNP tags rarer 
variants that arose after the tagging SNP became common (synthetic 
association) (Figure 2). Both these hypotheses were discussed earlier.
The International Hap-
Map Project: is an in-
ternational effort to 
identify and catalog 
genetic similarities and 
differences in human 
beings. It describes 
what these variants 
are, where they oc-
cur in our DNA, and 
how they are distrib-
uted among people 
within populations and 
among populations. 
Tagging SNP: is a com-
mon polymorphism 
that is in high LD with 
other variants and rep-
resents them. These 
SNPs are used in GWAS 
to map regions of asso-
ciation to disease. 
Linkage disequilibrium 
(LD): is the association 
between two loci and 
reflects the probability 
for variants being in-
herited together more 
often than would be 
expected by chance. 
Haplotype: the se-
quence of alleles inher-
ited together.
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Figure 4  Scheme of steps taken to identify candidate variants. Hypothesis-driven: 
knowledge of the disease is used to find the candidate gene(s). Hypothesis-free: the 
candidate region is mapped. Information on the phenotype or protein function can be 
applied in the positional candidate approach. The candidate genes or regions (from hy-
pothesis-free and hypothesis-driven approaches) are screened for candidate variants 
(fine-mapping) with different techniques. All the techniques and their applications are 
explained in the text. 
Replication phase
 Replication of the findings in an independent study (either with a 
family-based or case-control design) is an essential step and will provide 
the most convincing evidence of a variant/gene causing the disease. Lack 
of replication may suggest a false-positive finding, but may also be due 
to genetic heterogeneity (described below) or a too small sample size.
 Allelic heterogeneity This occurs when different mutations in 
the same gene lead to the same disorder. This type of heterogeneity 
Homozygosity 
mappingLinkage analysis
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is often observed and it is therefore necessary to replicate the results. 
An entire gene/locus needs to be screened rather than just the single 
candidate variant. There are several examples of allelic heterogeneity 
underlying Mendelian and complex diseases, such as in ICF, a recessive 
immunoglobulin deficiency syndrome, which is caused by at least 
eleven different mutations in the same gene (40). MVID, an autosomal 
recessive disorder is caused by a wide spectrum of mutations in the 
MYO5b gene, including missense, nonsense,  deletion and splice-sites 
mutations (26), and this thesis). Three rare mutations in the NOD2 
gene have been associated with Crohn’s disease, possibly explaining 
association of the NOD2 locus to this complex disorder (14). Mutations 
located in different regions of the gene (functional domains, binding 
sites, etc.) can have a different effect on the severity of the disease, 
and are observed as genotype-phenotype correlations (4, 12). For 
example, some genes influencing lipid levels carry common variants 
with a modest effect size leading to complex traits, as well as rare 
variants with a large effect size and causing Mendelian dyslipidemias 
(41, 42). 
 Locus heterogeneity This occurs when mutations in different 
genes cause the same disease. Lack of replication of previously mapped 
candidate regions can be due to high locus heterogeneity. For example, 
two different linkage regions were mapped for celiac disease in two 
large, independent, families of Dutch origin (29, 31). In the case of 
complex diseases, it was proposed to investigate extreme phenotypes 
of the disease that would be due to a more restricted group of loci and 
therefore easier to map and replicate (30). For Mendelian disorders, 
the locus heterogeneity is not as common as for complex diseases 
but it does occur on a regular basis. Griscelli syndrome, an autosomal 
recessive disease, is caused by a mutation in one of three interacting 
genes, RAB27A-MLPH-MYO5A a tripartite complex, leading to one of 
the three subtypes of this syndrome (43). 
 Clinical heterogeneity This is when a mutation in the same 
gene leads to different diseases. For example, mutations in the RET 
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gene can lead to two totally different diseases depending on their 
position in the gene: Hirschsprung disease that affects the colon, 
and familial medullary thyroid carcinoma (44). Classic examples of 
clinical heterogeneity are two types of muscular dystrophies caused 
by different deletions in the DMD gene. One is an out-of-frame 
deletion leading to Duchenne muscular dystrophy (mostly fatal before 
adulthood), whereas the second is an in-frame deletion leading to 
Becker muscular dystrophy, which is not life-threatening (45).
 Population heterogeneity Each population differs in terms 
of allelic frequency, biological adaptation risk, and the prevalence 
of a disease. For severe Mendelian disorders, the mutated gene is 
more likely to be the same and mutations will occur with a very low 
frequency in each population as they undergo negative selection. 
Therefore, monogenic disorders are fairly replicable between different 
populations. The lack of replication of common SNPs associated to 
complex disorders in independent, case-control studies can be the 
result of genetic heterogeneity within a population due to genetic 
drift. As SNPs chosen from HapMap are fairly transferable between 
populations and create haplotypes due to LD, the transferability 
of a single SNP out of a group of correlated SNPs, rather than direct 
replication of the associated variant, might be a better way of replicating 
GWAS findings. This approach was successfully applied by Shiner et 
al. (2009), who replicated the results of association to a trait (adult 
height) in Europeans in an African population using two strategies: 
direct replication, in which only 8% of the loci were replicated, and 
locus-wide replication (transferability), in which 54% of the loci were 
replicated (46). 
Fine-mapping 
 Once the candidate region is mapped and successfully 
replicated, the next step is to fine-map it. Fine-mapping should narrow 
down the region or find the causative variant. The success of this step 
depends on the type of disease (complex, monogenic), the size of 
the region and its LD structure. The most common method is direct 
Genetic drift: is the 
change in the frequen-
cy of a variant (allele) 
in a population due to 
random sampling.
Transferability: is 
one of replication ap-
proaches in which all 
variants in high LD with 
the previously associ-
ated SNP (locus wide) 
are investigated for the 
association rather than 
single variants (direct 
replication).
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re-sequencing of the region, by conventional Sanger sequencing or 
by next-generation, high-throughput sequencing, which has been 
successfully applied to fine-mapping of loci for monogenic diseases. 
Fine-mapping of GWAS loci for complex diseases is much more 
complicated as all variants from the associated loci are in rather high 
LD. Thus, cross-ethnic mapping is one of the alternatives to break up 
large haplotypes (47).
 Cross-ethnic fine-mapping The concept behind this approach 
is to use unrelated populations to fine-map regions of high LD. 
Populations have different LD structures: older populations (Africans, 
Indians) are expected to have smaller LD blocks, whereas younger 
populations such as Europeans will have longer LD blocks (Figure 5). 
In order to fine-map the region with this method the first step 
is to determine the risk haplotypes in both populations and to check 
whether they share a common ancestor and could possibly tag the 
same risk variant. This is crucial as some loci are associated with disease 
by more than one independent signal, suggesting more than one risk 
haplotype (10). The next step is to compare the LD block between the 
two populations at the locus of the risk haplotype and to narrow down 
the region based on the smallest LD block (Figure 5). 
Figure 5  Fine-mapping of the candidate region using two populations of different 
linkage disequilibrium (LD) structure. In both populations the same loci were 
associated to the same diseases. The same or different causative variants are lying 
on the same haplotype. The haplotype in the older population is shorter due to the 
smaller LD blocks and can thus be used for fine-mapping the signal. The relevant 
narrower region is framed. 
Young population 
(e.g Dutch) of  large LD 
block at the risk locus
Old population (e.g Indians) 
of smaller LD blocks 
at the risk locus
Risk variant at the risk locus
Risk haplotype 
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This approach was successfully used to fine-map the IL2/IL21 region 
associated to celiac disease using Dutch and Indians populations (this 
thesis: Chapter 6). Such smaller haplotypes are more amenable for re-
sequencing studies and the availability of haplotypes from different 
populations can assist in interpreting the results of such studies. 
 Fine-mapping and re-sequencing by next-generation 
sequencing (NGS) Next-generation sequencing (NGS) is used for high-
throughput sequencing of the entire exome or genome of individuals 
for family-based or case-control studies. With the falling cost of NGS, 
it is rapidly becoming an alternative tool for the standard mapping of 
genetic diseases with problematic phenotypes (Mendelian or complex) 
in which GWAS simply does not tag the variant and a linkage method 
is not efficient because of de novo changes or locus heterogeneity 
(discussed earlier) (11). Since 2009, NGS has acquired high-throughput 
methods and become more affordable; a number of Mendelian 
disorders have been solved (48, 49) and causative variants have been 
found for some complex disorders (50). The difficulty of analyzing NGS 
data depends on the disease itself: looking for homozygous mutations 
causing recessive diseases is relatively easy compared to dominant 
disorders, as rare heterozygous sequence variants  are rather common 
in the genome (51). Still, the analysis for all study designs and disease 
types can be divided into two steps: the first phase is a well-designed 
filtering method of good quality, well-covered SVs, and the second 
phase is checking for co-segregation or the statistical relevance of the 
finding. The first phase should lead to the discovery of one or more 
candidate variants. Filtering steps will vary depending on the disease 
model (e.g. dominant or recessive) and the study design (e.g. family-
based or case-control design) and might include: (a) functionality of the 
SV, e.g. exon or coding regions, (b) the novelty or MAF of the SV, based 
on the publicly available data sets like 1000 Genomes project (51), 
HapMap (36), or a private data set such as Genome of the Netherlands, 
(c) conservation of the region containing the SV, (d) zygosity of the SV, 
(e) function of the gene containing the SV and its likely involvement in 
the disease, etc. In a case-control design, the same filtering needs to be 
Exome: is the genomic 
DNA representing all 
expressed messenger 
RNA sequences in any 
tissue.
1000 Genomes Project: 
the goal of this project 
is to find most of the 
genetic variants that 
have frequencies of 
at least 1% in the 
populations studied by 
using next-generation 
sequencing technology.
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applied for a representative number of cases and controls (18, 20). If 
the number of variants after filtering is still high, other information can 
be added in order to filter out non-causative SVs. For example, Norton 
et al. (2011) applied expression data from the heart, assuming that a 
causative gene for dilated cardiomyopathy must be highly expressed 
in this organ (52). The second phase is to investigate the correlation 
between the sequence variants and disease by co-segregation of the 
selected SVs in families or testing for enrichment differences between 
cases and controls by applying appropriate statistical tests that pool 
together filtered SVs at a selected locus and testing them collectively 
(burden test) (53, 54). To prove the significance of a finding, we need 
to demonstrate replication by screening a large control panel and 
performing functional follow-up studies. NGS has been successfully 
applied to investigate a wide spectrum of diseases, such as autosomal 
dominant diseases (55), sporadic cases caused by de novo mutations 
(56), mitochondrial disease (57), X-linked diseases (58), autosomal 
recessive diseases (59), complex diseases with Mendelian-like 
segregation (50), and complex diseases in a case-control design (18, 19). 
Nowadays NGS rather than Sanger-type sequencing is used 
for the efficient and fast screening of previously mapped regions. 
Candidate loci from linkage analysis are of the standard size of around 
10-30 cM (= 10-30 Mb) and contain some 100-300 candidate genes 
(60). Loci associated in GWAS are smaller and contain fewer genes, but 
each of the complex diseases is associated to many such loci (61). The 
high number of genes and lack of a high-throughput screening method 
previously restricted the fine-mapping of candidate loci. But since 
NGS technology has become feasible and affordable, researchers have 
been able to screen for mutations in candidate regions by enriching for 
the entire exome and further analyzing regions of interest (55), or by 
achieving a very high coverage from enriching for selected regions of 
interest (62-64) (Figure 6). 
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Figure 6  Targeted enrichment of genomic DNA. Genomic DNA is isolated and its 
quality is checked (1). It is then sheared into small fragments (2) and selectively at-
tached to the enrichment oligonucleotides (3) as the platform contains probes for 
regions of interest (on target). Sequences “off target” are washed off, whereas “on 
target” sequences are amplified and eluted (4) from the platform to be submitted for 
further sequencing (5).
In conclusion, NGS is proving to be a very powerful approach, 
which can be used as a screening method for hypothesis-driven as 
well as hypothesis-free approaches to investigate both Mendelian 
and complex diseases (Figure 4). With targeted re-sequencing (e.g. 
by exome enrichment), it is proving possible to solve most of the 
Mendelian disorders in a fast and efficient way. In the future, whole 
genome sequencing could be the best method for investigating complex 
diseases, as not only coding variants but regulatory and miRNAs can be 
re-sequenced. Both methods are being continually improved: exome 
enrichment capture is becoming more complete, containing more of 
the expressed regions, although whole genome technology yields a 
better coverage at the moment.
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Abstract 
Objectives. Microvillus inclusion disease (MVID) is a rare autosomal recessive 
enteropathy characterized by intractable diarrhea and malabsorption. Recently, 
various MYO5B gene mutations have been identified in MVID patients. Interestingly, 
several MVID patients showed only a MYO5B mutation in one allele (heterozygous) 
or no mutations in the MYO5B gene, illustrating the need to further functionally 
characterize the cell biological effects of the MYO5B mutations. 
Methods. The genomic DNA of nine patients diagnosed with microvillus inclusion 
disease was screened for MYO5B mutations, and qPCR and immunohistochemistry 
on the material of two patients was performed to investigate resultant cellular 
consequences. 
Results. We demonstrate for the first time that MYO5B mutations can be correlated 
with altered myosin Vb mRNA expression and with an aberrant subcellular 
distribution of the myosin Vb protein. Moreover, we demonstrate that the typical 
and myosin Vb–controlled accumulation of rab11a- and FIP5-positive recycling 
endosomes in the apical cytoplasm of the cells is abolished in MVID enterocytes, 
which is indicative for altered myosin Vb function. Also, we report 8 novel MYO5B 
mutations in 9 MVID patients of various etnic backgrounds, including compound 
heterozygous mutations. 
Conclusions. Our functional analysis indicate that MYO5B mutations can be 
correlated with an aberrant subcellular distribution of the myosin Vb protein 
and apical recycling endosomes which, together with the additional compound 
heterozygous mutations, significantly strengthen the link between MYO5B and 
MVID. 
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at	 the	 apex	 of	 the	 intestinal	 epithelial	 cell	 monolayer	 provides	 a	 selective	 and	


















insertion	 in	 the	 MVID	 patients	 from	 the	 Turkish	 kindred.	 To	 date,	 25	 different	
nonsense,	missense,	splice	site,	or	in-frame	insertion	mutations	in	the	MYO5B	gene	
(OMIM#	606540)	have	been	identified	in	28	MVID	patients	from	consanguineous	
and	unrelated	marriages	 (10-12).	The MYO5B	 gene	encodes	myosin	Vb,	which	 is	




(heterozygous)	 or	 no	 MYO5B	 mutation	 was	 found	 (10).	 Moreover,	 although	
knockdown	of	myosin	Vb	in	human	epithelial	colorectal	adenocarcinoma	(Caco-2)	
cells	 recapitulates	most	of	 the	cellular	phenotypes	of	MVID	(12),	 it	 is	not	known	
whether	myosin	Vb	mRNA	and	protein	expression	and	myosin	Vb	function	is	affected	
in	MVID	 patients.	 Such	 information	would	 support	MYO5B	 gene	 screening	 as	 a	
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imperative.	 In	 this	 study	 we	 have	 used	 small	 intestine	 biopsies	 to	 demonstrate	
that	MVID-associated	MYO5B	mutations	affect	the	expression	and	function	of	the	
myosin	Vb	protein	in	MVID	enterocytes.	In	addition,	we	have	performed	mutation	
analyses	of	 9	 additional	MVID	patients	of	 various	 ethnic	 background	 and	 report	
8	 new	 MYO5B	 mutations;	 three	 homozygous	 and	 five	 heterozygous	 mutations	
which	 include	 stop	 codons/nonsense	mutations,	missense	mutations,	 splice	 site	
mutations,	large	deletions,	and	compound	heterozygous	mutations.
Materials and methods
Description of patients and clinical history 
	 Nine	patients	in	whom	histological	examination	of	small	intestine	mucosa	
confirmed	 the	 diagnosis	 of	MVID	were	 included	 in	 this	 study.	 Patients	 1-6	were	
collected	from	a	larger	patient	cohort	that	received	a	bowel	transplant	via	the	Liver/






(first	 cousins).	 She	 has	 two	 sisters	with	MVID	one	 of	which	 is	 patient	 2.	 Patient	
4	 is	 a	 1	 year	 old	 Navajo	 Indian	 male	 with	 early-onset	MVID	 of	 related	 parents	
(died	of	sepsis).	Patient	5	 is	a	12	year	old	Navajo	 Indian	 female	with	early-onset	
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was	diagnosed	with	 late-onset	MVID.	Unaffected	parents	 and	 siblings	 of	 patient	




consanguineous	 parents	 who	 presented	 severe	 secretory	 diarrhea	 and	 nutrient	




DNA and RNA isolation
	 DNA	was	isolated	from	peripheral	blood	samples	using	standard	laboratory	
procedures.	DNA	and	RNA	from	saliva	was	also	collected	and	isolated	(OrageneDNA	
and	 OrageneRNA,	 DNA	 Genotek	 Inc,	 Ottawa,	 Canada).	 RNA	 from	 in	 liquid	
nitrogen	 snap-frozen	 biopsy	 samples	 was	 isolated	 after	 homogenization	 using	 1	
mm	glass	beads	using	Trizol	 (Invitrogen,	Carlsbed,	CA).	Concentration	and	purity	
were	 determined	 with	 NanoDrop	 ND-1000	 (Isogen	 Life	 Science,	 De	Meern,	 the	
Netherlands).
RT-PCR
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sequenced	 in	 probands.	 Their	 relatives	 and	 approximately	 50	 control	 individuals	
(~100	chromosomes)	were	screened	for	the	detected	mutations.	Primers	for	PCR	
amplification	(supplementary	tables	1	and	2	show	primers	used	for	amplification	
of	 genomic	 DNA	 and	 cDNA,	 respectively)	were	 designed	 using	Primer321	 on	 the	
genomic	 sequence	 of	 MYO5B	 (NC_000018.8)	 and	 its	 mRNA	 (NM_001080467).	
The	PCR	reaction	was	performed	with	50ng	genomic	DNA	in	20ul	reaction	volume	













.	 The	 PCR	 conditions	 differed	with	 respect	 to	 the	 annealing	
temperatures	 and	 buffers	 used.	 Initial	 denaturation	 at	 95°C	 for	 5	 min	 (4	 min	
Buffer-B);	 40	 cycles	 (33	 cycles	 Buffer-B)	 of	 denaturation	 at	 95°C	 for	 30	 s	 (1	min	
Buffer-B),	annealing	for	30	s	(1	min	Buffer-B),	and	extension	at	72°C	for	30	s	(2	min	







	 In	 order	 to	 detect	 large	 deletions	 in MYO5B	 in	 patient	 7,	 real-time	
quantitative	PCR	was	used	 to	determined	copy	numbers	of	 the	exons.	Reactions	
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antibodies,	 washed,	 and	 incubated	 with	 appropriate	 horseradish	 peroxidase-




Rab11a	 sequence	 (Zymed	Laboratories	 Inc);	polyclonal	 antibodies	against	Rip11/
FIP5	 (13);	polyclonal	antibodies	 raised	against	a	 synthetic	peptide	corresponding	
to	 C-	 or	 N-terminal	 residues	 (amino	 acids	 1093-1112	 or	 23-41,	 respectively)	 of	
human	myosin	 Vb	 (Antagene	 Inc;	 60B923)	 that	 recognizes	 a	 single	 band	 of	 the	
appropriate	molecular	mass	of	~214	kDa	on	Western	blot;	Horseradish	peroxidase-
conjugated	 donkey	 anti-rabbit,	 sheep	 anti-mouse	 antibodies	 (GE	 Healthcare).	
Immunohistochemistry	images	show	villus	cells.		
Results
Eight new MYO5B mutations associated with nine microvillus inclusion disease 
patients








Patient	 1	 carries	 a	 homozygous	 non-conservative	 missense	 mutation	 in	
exon	8	(c.946G>A,	p.Gly316Arg),	which	replaces	a	small	aliphatic	glycine	(conserved	
in	myosin	Va	and	Vc;	 Supplementary	figure	1)	with	a	 large	and	charged	arginine	
in	 the	 protein’s	 conserved	 head	 domain	 region.	 In	 patients	 2	 and	 3	we	 found	 a	
shared	homozygous	deletion	 in	exon	19	 (c.2330_del	G;	Supplementary	figure	2).	
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This	mutation	 disturbs	 the	 reading	 frame	 and	 leads	 to	 a	 premature	 stop	 codon	
(p.Gly777AsnfsX6;	 Supplementary	 figure	 3)	 in	 the	 first	 calmodulin-binding	 IQ1	









For	 patient	 7,	 8	 and	 9,	 we	 also	 obtained	 DNA	 samples	 from	 unaffected	
siblings	 and/or	 parents.	 Patient	 7	 reveals	 a	 compound	 heterozygous	 mutation,	
which	 includes	 a	 paternal	 allele	 with	 a	 non-conservative	 asparagine-to-serine	
(c.1367A>G,	p.Asn456Ser)	substitution	in	exon	11	of	the	head	domain	(Figure	1A,	
B,	D)	 (conserved	 in	myosin	Va	and	Vc;	 Supplementary	figure	5),	 together	with	 a	
missense	variant	p.Met1688Val	(c.5062A>G)	in	exon	37	(p.Met1688	is	substituted	
in	 MYO5A	 and	 MYO5C;	 Supplementary	 figure	 6).	 p.Met1688Val	 represents	 an	
infrequent	polymorphism,	as	it	was	found	in	Polish	and	Dutch	controls	with	allele	




could	 possibly	 point	 towards	 a	maternal	 transmission	 of	 a	 deletion.	 Using	 real-
time	PCR	to	determine	the	copy	number	of	the	MYO5b	gene,	we	found	that	the	
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domain	 that	 is	 associated	 with	 actin-binding	 (14-17)	 (Figure	 1D).	 All	 mutations	
identified	 in	 this	 study	are	 listed	 in	Table	1.	The	position	of	all	mutated	residues	
in	the	crystal	structure	of	the	myosin	Vb	head	domain	are	depicted	in	Figure	1D.




MYO5B mutations affect the expression and function of the myosin Vb protein in 
MVID enterocytes
	 We	analyzed	 the	expression	 levels	 of	myosin	Vb	mRNA	 from	biopsies	of	
patients	8	and	9	by	real-time	PCR	and	compared	these	to	control	patients.	In	patient	
8,	myosin	Vb	mRNA	expression	was	reduced	by	50%	when	compare	to	14	non	MVID	









used	 in	 the	 synthetic	peptides	 to	 generate	 these	 antibodies,	 and	 the	 antibodies	
should	recognize	the	mutant	protein	if	present.	The	lack	of	clear	myosin	Vb	signal	




Myosin	 Vb	 regulates	 the	 subcellular	 positioning	 of	 recycling	 endosomes	
by	binding	to	small	GTPase	Rab	proteins	such	as	Rab11a	at	 the	cytosolic	surface	
of	 endosomes	 and	 attaching	 these	 endosomes	 to	 and	moving	 them	 along	 actin	
filaments	 (19-24).	 Alterations	 in	 the	 typical	 spatial	 organization	 of	 recycling	
endosomes	 in	MVID	enterocytes	can	therefore	be	used	as	a	read-out	 for	altered	
myosin	Vb	 function.	To	address	 this,	 the	expression	and	distribution	of	 recycling
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Figure 1. Identification and mutation analysis of MYO5B in MVID patients and parents/siblings. 
A)	 Pedigrees	 in	 three	 families	 with	 MVID	 patients	 7,	 8	 and	 9	 (designated	 P7,	 P8,	 and	 P9).	 The	
c.1540T>C	substitution	 in	patient	9	 is	a	de novo	mutation	on	 the	paternal	 chromosome	 (indicated	
with	asterisk).	Haplotype	analysis	in	patient	7	and	her	family	was	indicative	for	a	deletion	in	MYO5B 
on	the	maternal	chromosome.	The	MYO5B	variants	tested	were	(top	to	bottom):	c.1367A>G	(exon	
11),	 c.3276+11	 (rs2276176,	 intron	24),	 c.4222-73	 (rs490648,	 intron	31),	 c.4315+5	 (rs488890	 intron	
32),	 c.5062A>G	 (exon	 37),	 c.5313+72(rs621101,	 intron38)	 B)	MYO5B	mutations	 identified	 in	MVID	
patients.	 C)	 Deletion	 mapping	 results	 of	 patient	 7.	 The	 maternally	 derived	 deletion,	 spanning	
exons	2–12,	was	determined	by	quantitative	PCR	using	DNA	 from	the	proband’s	brother	 (2	 copies	
for	 each	 exon)	 to	 normalize	 the	 signal.	 D)	 Ribbon	 diagram	 of	 the	 nucleotide-free	 structure	 of	
the	 motor	 domain	 of	 chicken	 myosin	 V	 (rigor-like/strong	 actin-binding	 state,	 PDB	 code:	 1OE9),	
indicating	 the	 locations	of	mutated	 residues	 (figure	prepared	with	PyMOL	 (DeLano	Scientific	LLC)).
Figure 2. Real-time 
PCR detection of 
myosin Vb mRNA and 
immunohistochemical 
labeling of myosin Vb. 
A)	 RNA	 was	 extracted	
from	 small	 intestinal	
biopsies	 of	MVID	 patient	
8	 and	 9	 (designated	 P8	
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Figure 3. Immunohistochemical labeling and variant analysis of Rab11a and FIP5(/Rip11).	 A)	




Figure 4. Immunohistochemical labeling of early endosome-, late endosome/lyosome, and Golgi-
associated proteins.	The	subcellular	distributions	of	giantin,	EEA1	and	LAMP-1	in	control		and	MVID	
enterocytes	 (patient	 9	 (P9))	 are	 shown.	Negative	 (non-immune	first	 antibody)	 control	 staining	 are	
shown	(ab	control).	
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endosome-associated	 proteins	 Rab11a	 (19-24)	 and	 the	 Rab11a	 effector	 protein	
















8	 new	mutations	 (~25%	 of	 all	 reported	mutations)	 including	 a	 large	 deletion,	 a	
single	nucleotide	deletion,	two	missense	mutations,	and	one	nonsense	mutation.	
We	also	report	two	additional	compound	heterozygous	MYO5B	mutations.	In	two	
patients	 we	 found	 a	 homozygous	 missense	 mutation	 that	 has	 been	 described	
previously	(11).	Our	study	adds	8	mutations	to	the	25	earlier	reported	by	Müller	and	





MYO5B	mutations,	24	are	 localized	 in	 the	N-terminal	head	domain	 that	 includes	
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are	 predicted	 to	 result	 in	 nonsense-mediated	 RNA	 decay	 (e.g.	 the	 homozygous	












It	 does	 so	 by	 interacting	with	 small	GTPase	Rab	proteins	 such	 as	 Rab11a	 at	 the	
cytosolic	 surface	 of	 recycling	 endosomes	 and	 coupling	 these	 endosomes	 to	 and	
positioning	them	along	actin	filaments.	We	demonstrate	that	the	typical	and	myosin	
Vb–controlled	 accumulation	 of	 Rab11a-	 and	 FIP5-positive	 recycling	 endosomes	
in	the	apical	cytoplasm	of	the	cells	 is	abolished	 in	MVID	enterocytes.	These	data	
are	indicative	for	an	altered	myosin	Vb	function	in	MVID	enterocytes.	It	should	be	
noted	 that	our	conclusions	are	based	on	 two	cases	of	 this	 rare	disease	and	 that	
future	 experiments	 are	 necessary	 to	 further	 consolidate	 these.	 Further	 in-depth	
analysis	of	MYO5B	mutations	and	their	molecular	and	cell	biological	consequences	
are	 warranted	 to	 expand	 our	 understanding	 of	 how	 they	 are	 related	 to	 MVID	
pathogenesis.	
It	 is	 encouraging	 that	 all	MVID	 patients	 (except	 for	 one	 (10))	 that	 have	
been	screened	 thus	 far	 carry	mutations	 in	 their	MYO5B	 gene,	and	 the	discovery	
of	 additional	 compound	 heterozygous	 mutations	 by	 Ruemmele	 and	 colleagues	
(12)	and	us	(this	study)	significantly	strengthens	the	correlation	between	MYO5B 
and	MVID.	 This	 correlation	 is	 further	 supported	by	 a	 recent	 study	 (12)	 in	which	
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endosome-associated	 and	 functional	 candidate	 proteins	 yielded	 MYO5B as a 
positional-functional	candidate	gene	in	this	patient	(this	text	:	Figure	1).	Sequencing	
of	 the	MYO5B	 gene	 in	 patient	 9	 revealed	 a	 homozygous	 stop	 codon	 in	 exon	 33	
(p.Q1456X;	c.4366C>T)	(main	text	:	Figure	1A).
Figure 1. Homozygosity mapping in patient # 9 .	The	position	and	length	of	the	homozygous	segments	
along	the	genome	are	indicated	together	with	the	location	of	candidate	genes	from	the	apical	recycling	
endosome	pathway.
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Abstract
Familial Mediterranean Fever (FMF) is an autosomal recessive auto-inflammatory 
disease, usually caused by mutations in exon 10 of the MEFV gene, coding for 
pyrin. Standard genetic testing could not provide a satisfactory diagnosis in a 
female patient with an autosomally dominant inherited periodic fever syndrome. 
She came from a non-consanguineous family of British descent. Whole exome 
sequencing revealed a novel missense sequence variant not seen in around 
6,800 controls, mapping to exon 8 of the MEFV gene (c.1730C>A; p.T577N). 
It co-segregated perfectly with the disease in this family. Other mutations at the 
same amino acid (c.1730C>G; p.T577S; c.1729A>T; p.T577S) were found in a family 
of Turkish descent, with autosomal dominant inheritance of an FMF-like phenotype, 
and in a Dutch patient. A mutation (c.1729A>G; p.T577A) was also detected in two 
Dutch siblings suffering from episodes of inflammation of varying severity but not 
resembling FMF. Peripheral-blood mononuclear cells (PBMCs) from one patient of 
our index family revealed increased basal IL-1β mRNA levels and cytokine responses 
after lipopolysaccharide (LPS) stimulation. Responses normalized under colchicine 
treatment. We conclude that heterozygous mutations at amino acid position 
577 of pyrin can induce an autosomally dominant auto-inflammatory syndrome. 
This suggests that T577, located between the coiled coil- and the C-terminal B30.2/
SPRY domains, is of crucial importance for pyrin function.
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Introduction
	 Auto-inflammatory	disorders	are	disorders	of	 the	 innate	 immune	system	
characterized	by	recurrent	episodes	of	fever	and	systemic	inflammation,	with	fever	
and	 localized	 inflammation	 predominantly	 affecting	 serosal	 surfaces,	 skin,	 joints	
and	eyes.	Attacks	are	often	self-resolving	and	there	are	no	signs	of	auto-antibodies	
or	infection	(1,	2).	
Auto-inflammatory	 syndromes	 may	 be	 inherited,	 such	 as	 Familial	
Mediterranean	Fever	(FMF),	TNF	receptor–associated	periodic	syndrome	(TRAPS),	





picture,	 the	 mode	 of	 inheritance,	 duration	 and	 frequency	 of	 attacks	 are	 often	
different	(2,	3).	In	addition,	many	patients	suspected	of	having	an	auto-inflammatory	
disease,	 do	 not	 fulfill	 the	 diagnostic	 criteria	 for	 the	 known	 auto-inflammatory	
syndromes	and/or	test	negative	for	the	known	mutations	in	genes	associated	with	
inherited	 auto-inflammatory	 syndromes.	 Correctly	 diagnosing	 these	patients	 can	
therefore	be	challenging,	as	shown	by	the	long	period	often	needed	for	diagnosis	(4).	
In	 a	 family	 with	 an	 autosomally	 dominant	 auto-inflammatory	
disorder,	 standard	 genetic	 testing	 did	 not	 provide	 a	 satisfactory	 diagnosis.	
We	 aimed	 to	 reveal	 the	 genetic	 cause	 of	 the	 autosomally	 dominant	
inflammatory	 symptoms	 in	 this	 family	 by	 using	 more	 advanced	 genetic	
methodology,	 such	 as	 a	 hypothesis-free,	 exome-wide	 sequencing	 approach.	
Material and Methods 
Patients
 Family 1.	 A	 female	 patient	 (IV:	 3)	 from	 a	 non-consanguineous	 family	 of	
British	descent	with	an	apparently	autosomally	dominant	inherited	periodic	fever	
syndrome	 (family	 4,	 Figure	 1A)	 suffered	 from	 recurrent	 episodes	 of	 synovitis,	
pleuritis	 or	 peritonitis	 and	 skin	 rash,	 from	 the	 age	 of	 6	 years.	 Her	 grandfather	 
(II:	1)	suffered	from	inflammatory	episodes	of	fever,	arthritis,	pleuritis,	peritonitis,	
and	skin	rash	from	the	age	of	10.	His	father,	two	of	his	siblings,	and	his	daughter	
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cells	 (PBMCs)	 from	one	affected	 family	member	 (III:	 2),	 and	one	healthy	 control	
subject.	We	carried	out	genetic	analyses	of	one	affected	and	one	unaffected	family	
members.
To	 check	 if	 the	 variant	 was	 a	 common	 polymorphism,	 we	 investigated	 
396	 healthy	 unrelated	 Dutch	 controls	 (from	 the	 genetic	 diagnostic	 department,	
Utrecht),	500	unrelated	Dutch	controls	from	the	GoNL	(Genome	of	the	Netherlands)	
project,	 from	 the	 1000	 Genomes	 Project	 (120	 CEU	 and	 118	 YRI	 controls	 )	 (5),	 
200	 Danish	 controls	 (6),	 120	 UK	 controls	 and	 an	 NHLBI	 GO	 Exome	 Sequencing	
Project	(ESP)	dataset	of	5,400	individual	controls.	
Exome sequencing: library generation, reference alignment and variant calling
	 The	genomic	DNA	samples	were	randomly	fragmented	using	nebulization.	
Barcoded	adapters	were	ligated	to	both	ends	of	the	resulting	fragments,	according	
the	 standard	NEBNext®	DNA	 Library	Prep	Master	Mix	 Set	 for	 Illumina®	protocol	
(New	England	Biolabs,	 	UK)	 (7).	Fragments	with	an	average	 insert	 size	of	220	bp	
were	excised	using	the	Caliper	XT	gel	system	and	the	extracted	DNA	was	amplified	













Aszperl_ProofPrint.indd   56 28-07-2012   00:02:07
Chapter III Autosomal dominant inheritance of FMF 
57
(http://snpeff.sourceforge.net)	the	variants	were	annotated	with	information	from	
dbSNP132,	 the	 1000	 Genomes	 Project	 (phases	 1,	 2	 and	 3)	 and	 Ensembl,	 build	
37.64.	 These	 programs	 are	 all	 integrated	 into	 the	MOLGENIS	 Compute	 pipeline	
developed	by	the	Genomics	Coordination	Center,	Department	of	Genetics,	UMCG	
and	 University	 of	 Groningen,	 the	 Netherlands	 (10)	 (http://wiki.gcc.rug.nl/wiki/
GccStart).	Pathogeneity	predictions	for	variants	were	obtained	from	PolyPhen	2.0,	
SIFT,	and	Align	GVD	(11	-	14).
Exome sequencing: step-wise filtering of the sequence data 
	 For	 our	 analysis	 we	 have	 used	 a	 “linkage-based	 strategy”	 analysis	 (15).	
We	have	chosen	all	sequence	variants	(SVs)	shared	between	two	affected,	related	
individuals	 (21,905	 SVs).	We	excluded	 all	 variants	 that:	 (1)	were	 reported	 in	 the	
131dbSNP	(including	1000	Genomes	Project)	and	in	private	sets	of	two	unrelated	
samples	(2,225	SVs	 left),	 (2)	mapped	to	the	 intronic	regions	of	the	genes,	except	
to	splice	sites	(565	SVs	left),	(3)	were	present	in	the	olfactory	receptor	genes	(16)	
and	 that	 had	 a	 high	 copy	 number	 genes	 (17).	We	 further	 reduced	 our	 dataset	
to	 151	 SVs	 by	 removing	 all	 variants	 in	 the	 homozygous	 stage	 (dominant	model	
of	 disease),	 present	 on	 the	 X	 chromosome	 (autosomal	model),	 and	 by	 using	 an	
updated	SeattleSeq	Annotation	tool	(18),	removing	additional	variants	present	 in	




Sequencing of 120 inflammasome related genes
	 We	generated	a	barcoded,	whole	genome,	fragment	library	for	the	patient	
in	 family	 4.	 The	 barcoded	 library	 was	 enriched	 from	 the	 coding	 regions	 of	 120	
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In vitro cytokine production
	 PBMCs	 were	 isolated	 using	 Ficoll-Paque	 Plus	 (Bio-Sciences	 AB).	 5x105 
cells	 in	 RPMI	 1640	 medium	 (Dutch	 modification;	 Invitrogen,	 Paisley,	 Scotland),	
supplemented	 with	 1 mM	 sodium	 pyruvate	 (Sigma-Aldrich),	 2 mM	 L-Glutamine	
(Merck)	and	50	μg/ml	gentamicin	(Centrafarm),	were	incubated	in	round-bottomed	
96-well	 plates	 (Greiner)	 at	 37°C.	 After	 24	 hours	 of	 incubation	 with	 various	
stimuli,	 supernatants	 were	 collected	 and	 stored	 at	 −80°C	 until	 further	 analysis.	









	 One	million	 freshly	 isolated	PBMCs	were	 incubated	with	 various	 stimuli.	
After	 incubation	 at	 37°C,	 total	 RNA	 was	 extracted	 by	 using	 TRIzol	 reagent	
(Invitrogen).	Isolated	RNA	was	subjected	to	DNAse	treatment	(Ambion®	DNA-free™ 
Kit,	 Invitrogen)	 and	 0.5	 μg	 RNA	was	 reverse-transcribed	 into	 cDNA	 using	 iScript	





lysis	 buffer	 (50	mM	Tris	 (pH	7.4),	 150	mM	NaCl,	 2	mM	EDTA,	 2	mM	EGTA,	 10%	
glycerol,	 1%	 Triton	 X-100,	 40	mM	 β-glycerophosphate,	 50	mM	 sodium	 fluoride,	 
200	μM	sodium	vanadate),	supplemented	with	protease	inhibitor	cocktail	(Roche)	
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developed	with	enhanced	 chemiluminescence	 (ECL,	GE	Healthcare)	 according	 to	
the	manufacturer’s	instructions.	
Results
Genetic cause of the auto-inflammatory disease in family 1
	 To	 search	 for	 gene	 candidates,	 we	 employed	 whole	 exome	 sequencing	
in	two	patients	from	family	1	(II:	1	and	IV:	3).	The	raw	sequencing	was	aligned	to	













Considering	 the	 patients’	 good	 response	 to	 colchicine,	 the	 mutation	 in	
the	MEFV	gene	was	the	most	likely	candidate.	We	further	tested	family	members	
for	how	 this	 variant	 segregated	with	disease.	As	 shown	 in	figures	1A	and	B,	our	
sequencing	confirmed	the	co-segregation	of	the	mutation	with	the	affected	family	
members.	More	 importantly,	 this	mutation	was	 not	 found	 in	 396	 healthy	Dutch	
controls,	200	Danish	controls,	120	UK	controls,	or	 in	 the	ESP	dataset,	nor	 in	 the	
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500	Dutch	controls	from	the	GoNL	project.	Neither	could	we	detect	this	mutation	
in	over	 1,000	patients	with	unexplained	 auto-inflammatory	 symptoms	 known	 to	
the	Department	of	Medical	Genetics,	UMC	Utrecht	or	the	Department	of	General	
Internal	Medicine,	Nijmegen.








Pyrin mutations in the same amino acid position in more families with auto-in-
flammatory diseases
	 At	 the	 Department	 of	 Medical	 Genetics,	 UMC	 Utrecht,	 three	 different	
mutations,	never	described	before,	affecting	the	same	amino	acid	location	of	pyrin	
had	previously	been	detected	in	three	other	patients	or	families.	
A	 c.1730C>G	 (p.T577S)	 mutation	 in	 MEFV	 (without	 other	 MEFV	 gene	




















Chapter 3 Figure 1A
Chapter 3 Figure 3B
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Figure 2. Pedigrees of (A) family 2 and (B) family 4 
variant	(c.800C>T	(p.T267I))	was	detected	in	a	Dutch	patient,	to	confirm	the	clinical	
diagnosis	of	FMF.	
Finally,	 sequencing	 of	 120	 inflammasome-related	 genes	 in	 a	 Dutch	
family	 with	 a	 very	 special	 clinical	 presentation	 also	 revealed	 a	 c.1729A>G	





and	 extreme	 anemia	 (Hb	 3.5	 mmol/l).	 Standard	 genetic	 testing	 for	 CAPS	 and	
DIRA	was	negative.	Under	anakinra	 treatment	 (a	synthetic	 interleukin-1	 receptor	
antagonist	blocking	 the	effects	of	human	 interleukin-1)	 this	patient	 is	now	doing	
well	 (Hb	 6.5	mmol/l	within	 one	month)	 and	 is	 catching	 up	 on	 her	 psychomotor	
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Chapter 3 Figure 2A
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and	 resembled	control	 levels,	 indicating	 that	 colchicine	 treatment	was	acting	on	
the	expression	of	IL-1β	mRNA	and	that	this	mutation	caused	higher	IL-1β	expression	
levels.
Next,	 to	 evaluate	 the	 functional	 consequences	 of	 T577N	 at	 the	 protein	
level,	LPS	stimulation	studies	were	performed.	As	shown	in	figure	3B,	the	patient’s	
cells	secreted	more	of	the	pro-inflammatory	cytokines,	IL-1β	and	IL-6,	after	3	hours	
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Chapter 3 Figure 3B











of	any	other	mutations	 in	 this	gene.	We	 identified	three	more	 families	who	also	
harbored	a	T577	mutation.	The	fact	that	four	rare,	novel,	DNA	variants,	affecting	
the	same	amino	acid,	were	detected	in	auto-inflammatory	patients	from	different	
populations,	 suggests	 that	 T577	 is	 of	 crucial	 importance	 in	 pyrin	 function.	 The	
classic	disease	caused	by	pyrin	mutations	 is	Familial	Mediterranean	Fever,	which	




Chapter 3 Figure 3A
Chapter 3 Figure 3C
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To	date,	 the	precise	structure	and	function	of	 the	pyrin	protein	have	not	




where	 about	 two-thirds	 of	 the	mutations	 are	 located	 (exon	 10),	 leading	 to	 the	
conclusion	that	many	mutations	are	close	to	a	predicted	peptide-binding	site	and	
suggesting	 that	 they	 are	 likely	 involved	 in	 altering	 the	 binding	 properties	 of	 the	
B30.2	domain.	 T577	 is	 located	between	 the	 coiled-coiled	domain	 and	 the	B30.2	
domain	 and	 structural	modeling	 based	 on	 an	 experimentally	 determined	 crystal	




its	 interaction	with	other	proteins,	or	 impairs	 its	 function,	such	that	 it	cannot	be	
compensated	for	by	the	correct	protein	product	encoded	by	the	other	allele.	The	





and	dendritic	 cells	 (26,	27),	where	 it	might	activate	NF-kB.	Pyrin	was	also	 found	
in	 the	 cytoplasm	 of	 monocytes,	 interacting	 with	 tubulin	 and	 co-localizing	 with	
microtubules	(28).	Through	the	pyrin	domain,	it	can	interact	with	ASC	(apoptosis-
associated	 speck-like)	 protein,	 which	 is	 involved	 in	 inflammasome	 complex	
formation	(29),	thereby	activating	IL-1β.	The	exact	role	of	pyrin	in	IL-1β	activation	
is	 not	 clear,	 because	experimental	 findings	fit	 in	with	 two	possible	mechanisms:	
either	pyrin	inhibits	IL-1β	activation	by	competing	with	caspase-1	for	ASC	(30,	31),	




Our	 cellular	 studies	 show	 that	 colchicine	 treatment	 in vivo	 inhibits	 the	
expression	 level	 of	 IL-1β	 (by	 almost	 six-fold	 compared	 to	 a	 control	 without	
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treatment),	 although	 further	 research	 is	 needed	 to	 pinpoint	 the	 mechanism	










persisted.	 There	 are	 a	 couple	 of	 possible	 explanations:	 the	 simplest	 one	 is	 that	
the	second	MEFV	mutation	was	not	found.	When	only	the	known,	most	common	
mutations	are	screened	for,	other	rare	or	novel	variants	will	not	be	detected,	and	
differences	 in	 genomic	 re-arrangements	 such	 as	 large	deletions	or	 copy	number	
variations	(CNV)	will	also	not	be	found.	However,	according	to	Van	Gijn	et	al,	single	
or	multi-exon	CNVs	of	the	MEFV	gene	do	not	contribute	to	the	mutation	spectrum	














a	 heterozygous	 carrier	 and	 a	 homozygous	 patient.	 Pseudo-dominant	 inheritance	
can	occur	 in	populations	with	a	high	carrier	 frequency	and	consanguinity,	which	
both	 apply	 to	 the	Mediterranean	 populations	 (45).	 This	 appears	 to	 be	 the	 case	
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in	several	studies	(46-48).	 In	our	study,	two	of	the	four	families	are	of	Dutch	and	




A	 different	 explanation	 for	 not	 finding	 a	 second	 mutation	 could	 be	 the	
phenomenon	 of	 mosaicism	 (49-51),	 whereby	 individuals	 carry	 cells	 of	 different	




As	 a	 final	 reason	 for	 not	 finding	 a	 second	 mutation,	 we	 would	 like	 to	
propose	that	FMF	(or	“pyrin-associated	periodic	syndrome”)	can	be	inherited	either	














It	 is	 of	 great	 importance	 that	 FMF	 patients	 are	 diagnosed	 correctly	 so	
that	 they	 can	 be	 treated	 appropriately.	 This	 is	 important	 in	 FMF	 to	 prevent	 the	
development	of	amyloidosis	(1).	For	example,	subject	III:2	of	family	1	was	about	70	
years	old	before	we	were	able	to	pinpoint	the	true	cause	of	her	auto-inflammatory	
symptoms.	 In	 the	meantime	 she	 had	 been	 incorrectly	 diagnosed	 several	 times,	
because	 symptoms	 of	 FMF	 overlap	 with	 other	 diseases,	 such	 as	 rheumatoid	
arthritis.	As	a	result,	she	also	suffered	side-effects	from	an	inappropriate	treatment.
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In	summary,	we	have	identified	a	family	with	a	truly	autosomal	dominant	
inheritance	 of	 FMF,	 caused	 by	 a	 single	 amino	 acid	 transition,	 on	 a	 single	 allele.	
This	T577	mutation	is	not	located	in	exon	10,	and	is	linked	to	autosomal	dominant	
inheritance	 of	 FMF,	 even	 in	 non-classical	 populations.	 Our	 finding	 in	 this	 family	
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Abstract 
Celiac disease is a multifactorial disorder caused by an unknown number of genetic 
factors interacting with an environmental factor. Hence, most patients are singletons 
and large families segregating with celiac disease are rare. We report on a three-
generation family with six patients in which the inheritance pattern is consistent with 
an autosomal dominant model. To date, 27 loci explain up to 40% of the heritable 
disease risk. We hypothesized that part of the missing heritability is due to low 
frequency- or rare variants. Such causal variants could be more prominent in multi-
generation families where private mutations might co-segregate with the disease. 
They can be identified by linkage analysis combined with whole exome sequencing. 
We found three linkage regions on 4q32.3-4q33, 8q24.13-8q24.21 and 10q23.1-
10q23.32 that segregate with celiac disease in this family. We performed exome 
sequencing on two affected individuals to investigate the positional candidate 
regions and the remaining exome for causal nonsense variants. We identified 12 
nonsense mutations with a low frequency (MAF < 10%) present in both individuals, 
but none mapped to the linkage regions. Two variants in the CSAG1 and KRT37 genes 
were present in all six affected individuals. Two nonsense variants in the MADD and 
GBGT1 genes were also present in 5 of 6 and 4 of 6 individuals, respectively; future 
studies should determine if any of these nonsense variants is causally related to 
celiac disease.
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Introduction
 Celiac disease (CeD) is a complex, autoimmune disease triggered by dietary 
gluten, which is widely available in cereals such as barley, rye and wheat. CeD is 
primarily a T cell-mediated immune disorder, in which CD4+ T cells recognize gluten 
peptides, resulting in a strong inflammatory response in the small intestine. CeD is a 
classic example of a multifactorial disease caused by many genetic factors, in addition 
to the environmental factor. It has been well established that the human leukocyte 
antigen (HLA) molecules HLA-DQ2 and -DQ8 play a key role in CeD pathogenesis 
(1, 2). These are also the most important genetic factors associated with the disease 
and explain some 35% of the heritability. Genome-wide association studies (GWAS) 
recently identified 26 non-HLA loci that contribute to CeD and explain an additional 
5% of the heritability with their modest effect size and odds ratios lower than 1.5. 
These loci comprise 69 genes that are mainly involved in the immune response 
(3). Family-based linkage studies may offer a powerful alternative to identifying 
more CeD genes with a larger effect size. However, there are few large families 
showing segregation of complex diseases such as CeD. In 2004, Van Belzen et al. 
(4) reported two linkage regions from a four-generation, Dutch CeD family with 
17 affected individuals. Direct sequencing of positional candidate genes from the 
9p13-21 region did not reveal causative mutations (5). The lack of high-throughput 
methods to investigate all the candidate genes from the large linkage regions 
hampered progress on this family, but work is ongoing. Recently, exome sequencing 
has been reviewed as a rapid, high-throughput tool for mutation screening (6) and 
successfully used to identify rare causal mutations, not only in Mendelian diseases 
(7) but also in complex diseases (8).
We analyzed a second, large CeD family of Caucasian origin with six patients 
segregating the disease across three generations and with suggested autosomal 
dominant inheritance. Linkage analysis revealed three potential loci on 4q32.1-q33 
(12 Mb), 8q24.13-8q24.21 (5 Mb) and 10q23.1-10q23.32 (10 Mb) chromosomes. 
We hypothesized that the causal variant responsible for CeD in this family would 
be a point mutation resulting in a non-functional protein product, and that it would 
be present in one of the linkage regions. To identify such a mutation, we performed 
exome sequencing of two affected family members to screen for nonsense mutations 
in the 148 genes making up the three linkage regions.
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 The family is Dutch of Caucasian origin and includes six CeD patients, 
all carrying the HLA-DQ2 genotype (Supplementary Fig. 1, Table 1). The detailed 
inheritance of the HLA-DQ2 and DQ8 risk genotypes is based on five tagging SNPs 
from the ImmunoChip that are specific for the HLA alleles present in the Dutch 
population (9).
 In this family, CeD affects approximately 38.5% of the offspring in the 
second generation. Four out of six of the affected individuals were diagnosed via 
a small intestine biopsy (Table 1). All the biopsies were re-evaluated and classified 
by a gastroenterologist (C.J.M.) as Marsh IIIa, IIIb, or IIIc (i.e. partial-, subtotal-, or 
total villous atrophy, with the presence of crypt hyperplasia and increased number 
of intraepithelial lymphocytes (30 per 100 enterocytes). Genomic DNA was isolated 
form peripheral blood to perform genotyping for linkage analysis and exome 
sequencing.
The study was approved by the ethics review board of the University Medical 
Center Groningen and written informed consent was obtained from all participants.
Table 1. Characteristics of a three-generation Dutch family affected by celiac disease. 
Individual Gender Year of birth Marsh status DQ Type Status for this study
CD0304-001 Female 1954 IIIa DQ2 Affected
CD0304-002 Male 1951 IIIb DQ2 Affected
CD0304-003 Female 1952 IIIb DQ2 Affected
CD0304-004 Female 1948 Undetermined DQ2 Affected
CD0304-005 Male 1947 IIIb DQ2 Affected
CD0304-006 Female 1984 Undetermined DQ2/DQ8 Affected
CD0304-007 Female 1985 Undetermined DQ2 Unaffected
CD0304-008 Female 1972 Undetermined DQ2 Unaffected
CD0304-010 Female 1982 Undetermined DQ2 Unaffected
CD0304-011 Female 1953 Undetermined DQ8 Unaffected
CD0304-024 Female 1919 Undetermined DQ2 Unaffected
CD0304-029 Male 1949 Undetermined DQX Unaffected
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Genotyping
 Six affected (CD0304-001, CD0304-002, CD0304-003, CD0304-004, CD0304-
005, CD0304-006,) and six unaffected (CD0304-007, CD0304-010, CD0304-011, 
CD0304-029, CD0304-008, CD0304-024) family members were genotyped using 
the ImmunoChip (10) (Fig. 1) as described in Illumina’s protocols. The National 
Center for Biotechnology Information (NCBI) build 36 (hg18) (Illumina manifest 
file Immuno_BeadChip_11419691_B.bpm) and the second-generation Rutgers 
combined linkage-physical map were used for mapping (11). The quality control 
was performed in Plink v1.07 (12). First we checked for any individuals missing more 
than 5% of the genotypes, but they all had more than 95% of the genotypes called. 
We removed all SNPs that had a genotype rate below 95%. We also checked for 
Mendelian errors using default values since we did not allow >5% Mendelian errors 
for the entire family, and any SNPs with >10% Mendelian error rate were excluded. 
We found no Mendelian errors. We included 174,624 SNPs in our study. The Dutch 
case-control data quality control was performed independently, as described in 
Trynka et al. (13).
Figure 1. Pedigree presenting the “affected only” part of the family studied and the segregation of 
seven nonsense sequencing variants (SVs). Affected individuals are marked in black.
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Chr. Gene  Position(mRNA) Position(protein) 
 9 GBGT1 c.363 G>T  p.Tyr121X      
 9 GNAQ  c.303 G>T  p.Tyr101X   
11 MADD c.2296 C>T  p.Arg766X
17 KRT37  c.703 A>G  p.Gln235X
17 KRT38  c.703 A>G  p.Gln235X
22 TPTE  c.571 A>G  p.Arg229X   
  X CSAG1 c.84 C>G  p.Tyr28X   
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Linkage analysis
 For our linkage analysis with the “affected only” approach, we used the 
data of selected markers from the 196,524 variants available on the ImmunoChip 
genotyping array for all 12 individuals (Fig. 1). We used Plink v1.07 for marker 
selection to apply stringent quality control on the ImmunoChip data, based on call 
rate (> 99%) and Hardy-Weinberg equilibrium (p > 0.001). We excluded indels and 
only considered highly polymorphic SNPs (MAF > 20%). SNPs showing any sign of 
Mendelian inconsistency were excluded. We then trimmed the dataset to limit 
biases associated with linkage disequilibrium, pruning SNPs so that each 50-SNP 
window contained no pair of SNPs with r2 > 0.2. Finally we included 8,750 markers 
for the analysis distributed equally over the genome, providing a sufficiently dense 
coverage to perform linkage analysis (Supplementary Fig. 2). The linkage information 
content was uniformly larger than 0.75 (14). Chromosome X was excluded from the 
linkage analysis as the results are often difficult to interpret. We used the second-
generation Rutgers combined linkage-physical map (11) for mapping the 8,750 
markers used in our linkage analysis.
Parametric and non-parametric linkage analysis was performed using 
Merlin v1.1.2 (15). The parametric model assumed a dominant inheritance with a 
disease probability of 1% for non-carriers and 80% for carriers. 
Exome sequencing: Library generation, reference alignment and variant calling
 Library generation, reference alignment and variant calling were performed 
at BGI, as described in Li et al., 2010 (16). In brief, 5 ug of high quality DNA from 
two individuals (CD0304-001 and CD0304-006) was fragmented and subsequently 
hybridized to a NimbleGen 2.1M Human Exome Array. This enrichment captures 
~30 Mb of coding DNA, which accounts for approximately 180,000 coding exons. 
Enriched exome DNA was amplified by PCR followed by random ligation of DNA 
fragments to the Illumina-compatible adapters and subjected to Solexa library 
preparation and single-run sequencing of 90 bp per read on average. Before 
alignment with the reference sequence, low quality reads (containing more than 
six Ns and/or 40 continuous identical bases and/or polluted by linker or adapter 
sequences) were removed. SOAPaligner (soap2.20) (17, 18) was used to align clean 
reads to the human reference genome (NCBI build 36.3) with a maximum of two 
mismatches allowed. SOAPsnp (19) was used for calling variants in the target region 
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and with the 500 bp up- and down-stream target regions referred to as “near target 
region”. We extracted genotypes which differed from the reference as candidate 
SNPs and kept only sequence variants with a quality score higher than 20, a depth 
between 4 and 200, an estimated copy number ≤ 2, and a distance between two 
SNPs of no more than 5, for further analysis. SOAPdenovo was used to identify 
insertions and deletions (indels) in the exome data by performing a de novo 
assembly of the sequencing reads. Assembled consensus sequences were aligned 
to the reference genome by a local alignment search tool Z (LASTZ) for aligning 
two DNA sequences, and inferring appropriate scoring parameters automatically 
and passed the alignment result to axtBes7t (20) to separate orthologous from 
paralogous alignment. Finally, we identified the breakpoints in the alignment and 
annotated the genotypes of the insertions and deletions. 
Annotation and filtration of the sequenced variants
 Each of the sequenced variants was annotated for functionality and 
frequency using the SeattleAnnotation tool (SeattleSeq Annotation, http://
gvs.gs.washington.edu/SeattleSeqAnnotation), annotate variation ANNOVAR 
(21) and an in-house pipeline. For MAF annotation, we used the whole 
genome sequencing of 60 individuals (120 genomes) of European origin from 
the 1000 Genomes Project (22) (vol1.ftp.pilot_data.release.2010_07.low_
converage). For our analysis we only included sequence variants with a MAF 
< 10% and only variants present in the exons and splice-sites: i.e. non-synonymous, 
nonsense, read-through variants and variants in the 3’ and 5’ UTRs. For the follow-
up study, we restricted our analysis to nonsense variants. We excluded nonsense 
variants present in olfactory genes and having a MAF > 10% in dbSNP132 from the 
follow-up study (here we considered only the MAF of established Caucasians and 
based on a greater number of chromosomes than in the 1000 Genomes Project). 
Nonsense variants present in our data from the exome sequencing of 16 CeD cases 
from eight Saharawi families (23) were also excluded. Finally, the candidate nonsense 
SVs were investigated for co-segregation with CeD in the study family. Fig. 2 shows 
a general flow scheme for our analysis. Indels were annotated using ANNOVAR 
(21) and sorting intolerant from tolerant (SIFT) (24) and filtrated separately. We 
considered novel indels (not present in the dbSNP data set) mapping to exonic and 
splice sites of the genes as interesting (annotation of the gene region was based on 
the University of California Santa Cruz (UCSC) database (25)).
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Figure 2. Filtering and follow-up scheme used in our analysis. We have presented a number of 
variants that correspond to each step taken.
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Sanger sequencing
 We validated variants by direct re-sequencing using a standard Sanger 
method (26). After filtering, the candidate variants were re-sequenced in the 
two exome-sequenced individuals (CD0304-001 and CD0304-006) for validation. 
If the variant was true and present in both individuals, we investigated its segregation 
in the entire family by re-sequencing it in the other 10 members. Details on the PCR 
and primers used for validation are summarized in Supplementary table 1.
Results
SNP-based linkage analysis
 Twelve family members were genotyped on ImmunoChip. After applying 
quality control, we performed genome-wide, parametric (dominant model) and 
non-parametric analysis. We found three loci with non-parametric analysis and with 
a non-parametric LOD score (NPL) of ~2.40 on 4q32.3-4q33 (p = 0.0004), 8q24.13-
8q24.21 (p = 0.0004) and 10q23.1-10q23.32 (p = 0.0004), which together contained 
148 genes (Table 2). Parametric linkage analysis did not identify any more regions 
with a LOD score > 2. From non-parametrical and parametrical linkage analysis, we 
identified six suggestive regions with 1 < NPL < 2, and four suggestive regions with 
1 < LOD < 2 (Supplementary table 2). Some of these regions overlap and others are 
specific for a single analysis (Table 2, Supplementary table 2).
Table 2. Three linkage regions with a non-parametric LOD score of ~ 2.





4q32.3-4q33 5.2 29 Non-parametric 2.40 0.0004
8q24.13-8q24.21 5.0 39 Non-parametric 2.41 0.0004
10q23.1-10q23.32 9.7 80 Non-parametric 2.41 0.0004
Evaluation of the exome sequencing data
 Because of the large number of genes (148) present in the linkage regions, 
we decided to perform exome sequencing in two affected individuals (CD0304-
001 and CD0304-006) (Fig. 1). After enriching for ~30 Mb of coding sequence, we 
obtained on average 2.5 Gb of mapped sequence data per individual. The median 
exome coverage was 44-fold with 94% of the target region covered with a minimum 
of 10x (Supplementary table 3). On average, per individual, we identified 18,000 
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high quality (Q > 20) sequence variants in the coding regions (Supplementary 
table 4). To exclude any possible mix-up of samples and for extra validation of the 
sequenced data, we compared their genotypes from the ImmunoChip platform 
with their sequenced variants. We observed a concordance > 98% between the two 
datasets, indicating no sample mix-ups and suggesting a high level of confidence for 
the sequenced data. We also showed that the concordance between the sequenced 
individuals was ~ 53%, which is in agreement with the genetic distance between 
the two family members. More detailed statistics of the sequences and SVs can be 
found in Supplementary tables 3 and 4.
Table 3. Details of seven nonsense sequence variants shared by two exome-sequenced individuals.





9 rs35898523 g.135019466 c.363 G>T p.Tyr121X
GNAQ Guanine nucleotide-
binding protein alpha-q
9 g.79726915 c.303 G>T p.Tyr101X
MADD MAP-kinase activating death domain 11 rs35233100 g.47263206 c.2296 C>T p.Arg766X
KRT37 keratin-37 17 g.36832585 c.703 A>G p.Gln235X





21 rs1810540 g.9964627 c.571 A>G p.Arg191X
CSAG1 chondrosarcoma associated gene 1 X rs1894360 g.151659501 c.84 C>G p.Tyr28X
Inclusion filtering of sequence variants
 To identify potential disease-causing variants, we adapted a filtering and 
follow-up scheme that assumed the disease in both family members was due to 
the same causal variant (Fig. 2). Furthermore, we only included variants with a MAF 
< 10% in the 1000 Genomes Project dataset and having functional effects on the 
protein product (i.e. missense, splice site, nonsense, read-through variants and 
SVs from UTRs) (Fig. 2). As the linkage regions are identified with 95% confidence, 
we could still miss the real disease-causing mutation. Hence, we also applied the 
same filtering criteria to the entire exome. In total, we identified 846 candidate SVs 
when we combined the linkage regions (2 SVs) and the exome-wide data (844 SVs) 
(Fig. 2, Supplementary table 5A). Due to the large number of candidate SVs to be 
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investigated, we decided to continue the follow-up studies for only the 12 nonsense 
variations as these are the most damaging (27), although none of them were located 
in the three linkage regions. We excluded nonsense variants in olfactory genes 
and those having a MAF > 10% in dbSNP132 and present in our in-house set of 
Saharawi samples from further analysis (Fig. 2). We also removed the variants in the 
CDC27 gene due to the high number of SNPs in the exons; leaving seven nonsense 
variants to be investigated for co-segregation in the family (Table 3, Supplementary 
table 6A). The segregation of these variants in the family is shown in Fig. 1. Three 
variants in the GNAQ, KRT38 and TPTE genes were false-positive, meaning that we 
could not validate these SVs by Sanger sequencing; two variants in the CSAG1 and 
KRT37 genes co-segregate fully with the disease and are present in all the affected 
individuals; and two other variants are present in the MADD and GBGT1 genes in 
5 of 6 and 4 of 6 of the affected individuals, respectively.
To account for the possibility of unequal coverage of sequence in the two 
family members (CD0304-001 and CD0304-006), we also analyzed them separately 
and identified an extra 29 and 23 nonsense variants, respectively (Supplementary 
table 5B). Again, none of these were located in the three linkage regions. Some were 
present in both individuals and had already been included in the initial analysis, while 
some were found in only one individual. After applying our final inclusion criteria 
and discarding one variant in PRAMEF gene due to the high number of SNPs in the 
exons, we investigated 20 SVs that were present in only one individual for validation 
in the second individual (Supplementary table 6B). None of these were investigated 
for co-segregation, since 18 could not be confirmed in the second individual, one 
was false-positive and one, in the TPTE gene, we failed to validate with Sanger 
sequencing due to the presence of small deletions surrounding the candidate SV.
We applied a separate annotation and filtration to the indels, so that they 
included only novel variants that mapped to the exonic regions and were present 
in both individuals. In total, we identified 3,258 shared indels, of which 92 were 
novel (not present in the dbSNP dataset) and mapped to the exons or splice sites 
of known genes (UCSC was used as a reference). Nine out of 92 were found in the 
regions of suggestive linkage; two mapped to the exonic regions but did not change 
the frame, and seven mapped to 3’UTRs (Supplementary table 7), but none were 
found to be present in the linkage loci of NPL > 2. 
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Discussion
 We studied a three-generation Dutch family of Caucasian origin with 
a dominant-like segregation of CeD to find causative variants that might have 
a substantial effect on the inherited disease risk. To map the candidate variants, 
we combined linkage analysis with an “affected only” approach of the entire family 
with exome sequencing of two affected individuals. As the inheritance model of 
CeD in the family is uncertain, we also applied a non-parametric linkage approach 
in addition to the parametric analysis. Both analyses gave comparable results, 
whereas applying the wrong model for parametric analysis can result in loss 
of power for detecting linkage (14). We identified three candidate regions using 
a non-parametric analysis with NPL > 2 but were not able to detect a region with 
LOD > 2 using parametric analysis. None of the regions overlaps with previously 
identified CeD loci (3).We did not observe linkage to the HLA region on 6p21 in this 
family, despite the fact that the HLA-DQ2 and DQ8 loci are the strongest risk factors 
contributing to CeD. Because HLA-DQ2 and DQ8 alleles are also very common in the 
general population (~30%), the risk alleles were also inherited from an unaffected 
parent who married into the family (Supplementary Fig. 1), thereby disrupting the 
proper segregation of alleles in the family. Hence, linkage to HLA was not identified 
by our linkage analysis.
CeD is genetically heterogeneous, like other complex diseases, and even 
within a single family where the inheritance of the disease is compatible with a 
dominant model, it is likely that multiple loci co-segregate with the disease. Our 
detection of three linkage regions in this family is in line with a previous linkage 
analysis in a CeD family in which two regions were found to segregate significantly 
with CeD (4). The regions found in both families do not overlap, which may also 
indicate a high heterogeneity for CeD.
In order to identify causal variants, we hypothesized that these variants 
would be present in the candidate linkage regions and shared by both the affected 
family members we sequenced. As the three candidate linkage regions together 
contain 148 genes, exome sequencing is an efficient method to screen all the 
positional candidate genes for disease-causing variants. At the same time, this 
technology also allowed us to scrutinize the remainder of the genome in case our 
linkage analysis proved incorrect. We also hypothesized that within our multi-
generation family a limited number of causal variants with substantial risk would be 
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present. We therefore focused our analysis on nonsense variants as these are the 
most damaging (27). 
After applying our filter criteria to the linkage regions and to the entire 
exome, we were left with seven nonsense variants, none of which mapped to the 
linkage regions. After validation by Sanger sequencing, three of them were found to 
be false-positive, in the GNAQ, KRT38 and TPTE genes. The remaining four SVs were 
investigated for co-segregation with the disease. We were looking for a dominant-
like inheritance, but we kept in mind that a low-frequency, causative variant for a 
complex disease does not have to demonstrate Mendelian segregation but can still 
contribute to the heritability of the disease (28). Two SVs in the CSAG1 gene (p.Tyr28X) 
and KRT37 (p. Gln235X) were present in all six affected individuals. Regions with 
these variants were not identified in the linkage analysis because the CSAG1 gene 
lies on the X chromosome, which was not submitted for linkage analysis, as it is so 
difficult to analyze. A variant in the KRT37 gene was also present in the unaffected 
spouse that contributed to the “affected only “approach and was thus not picked 
up in the linkage analysis. The presence of this variant in unaffected spouses could 
indicate a higher MAF than found in the 1000 Genomes data set, thus case-control 
genotyping is required for future follow-up studies. Neither gene has an immune-
related function: the CSAG1 gene is reported as a cancer/testis antigen highly 
expressed in cancer tissues (29), whereas the KRT37 gene belongs to the type I keratin 
gene family and is involved in the hair follicle and expressed in epithelial cells (30). 
A nonsense variant in the MADD gene (p.Arg766X) was present in 5 of 6 
affected family members, and a nonsense variant in the GBGT1 gene (p.Tyr121X) 
was found in 4 of 6. Thus, neither of these variants segregates fully with the 
disease, but, interestingly, both of the variants were present on the ImmunoChip 
which was recently used for CeD case-control studies in 2,312 individuals of Dutch 
origin. There was no significant association found as the p values associated with 
these variants were p = 0.80 (MAF=0.059) for MADD2 and p = 0.78 (MAF=0.079) 
for GBGT1 in the Dutch cohort. The MADD gene was also found to be associated to 
type 2 diabetes (31) and it interacts with TNFR1 to activate MAPK and propagate 
apoptotic signals (32). The GBGT1 gene is a member of the ABO family that may be 
involved in tropism and the binding of pathogenic organisms (33).
As the coverage of some regions in our sequencing data could be unequal, 
we also investigated the nonsense variants in both samples separately. 20 SVs that 
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were present in only one of the sequenced individuals were investigated further: 
18 of 20 genotypes identified in the exome data agreed with the genotypes found in 
the independent validation step. The variant in the ZNF81 gene was from a different 
genotype than in the exome for individual CD0304-006 (Supplementary table 5). 
The coverage in this region was very low (~2 on average) and this could explain the 
false-positive calling. We were not able to validate a SV in the TPTE gene with Sanger 
sequencing due to the presence of several deletions surrounding the candidate 
variant. As none of the remaining true SVs were present in both patients, we did not 
study them for segregation in the family. In summary, we identified seven nonsense 
SVs that were shared by the two exome-sequenced patients, but none were located 
in the linkage regions.
There were a number of weaknesses in our study. First, we assumed that 
both the affected and sequenced individuals shared the same causal variant, but 
given the observation of multiple linkage regions in families segregating for complex 
diseases, this assumption might not be valid. Second, we assumed that the causal 
variants segregating in a multi-generation family would be nonsense variants, but 
this might be too stringent and other type of variants possibly influencing protein 
expression could be followed up in future studies. Risch (34) proposed that while 
looking for variants causing complex diseases, we should focus on non-synonymous, 
coding, and 3’ and 5’ UTRs variants. If we had concentrated on these categories, 
we would have had 846 variants (844 exome-wide and two from linkage regions) 
to study further. The two variants identified in the linkage regions mapped to the 
untranslated regions of two genes: TLL1 and SLC16A12. The variant in SLC16A12 
might be a private variant as it has not been reported in any of the public databases. 
We investigated the co-segregation of these variants in the family. Minor alleles of 
the variant in the TLL1 gene were present in 5 of the 6 affected family members 
and in 6 of the 6 affected family members in the SLC16A12 gene (Supplementary 
Fig. 3). Using the Patrocles algorithm (35), we could verify the consequences of the 
change on miro RNA (miRNA)-binding sites. We observed that variants introduce 
new miRNA binding sites, which may have functional consequences. However, more 
extensive case-control and functional studies are needed to prove their potential 
involvement in the pathogenesis of celiac disease. 
From the 844 SVs identified, 27 mapped to the 10 regions of suggestive 
linkage (NPL and/or LOD > 1 and < 2). Interestingly, the region on chromosome 
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8q24.13-8q24.21 was also identified as suggestive in parametrical analysis. 
As recently proposed in a review by Cirulli and Goldstein (6), the investigation of 
suggestive linkage regions combined with the prioritization of candidate genes 
is also a way to narrow down the causative variant. We could therefore use this 
knowledge for future studies in this family. 
It seems that an attractive approach might also be to follow up the missense 
variants with a MAF < 5% (27), however, we would still be left with a large dataset 
of 502 missense SVs.
We have found 92 exonic, novel indels present in both individuals exome-
wide. None of these mapped to the linkage regions with NPL > 2 and nine were 
found to be present in suggestive linkage regions: seven in the 3’ UTR regions and 
two in protein-coding regions, but not disturbing the protein frame. Because none 
of these indels were very strong candidates and changes in the UTRs are difficult to 
interpret, we did not follow up any of these indels. 
From recent case-control studies we know that there is an excess of rare 
missense and nonsense variants in GWAS regions for complex diseases (36, 37). 
However, none of the seven nonsense variants that we identified mapped to loci 
previously associated with CeD. Of the 846 SVs, only one mapped to a CeD locus: a 
missense variant (p.Lys1385Asn) in the LRRC37A2 gene. Apparently the function of 
this gene is not well established. 
Finally, is possible that the approach we have taken is not appropriate for 
complex diseases. It might well be that sequencing two individuals is not enough 
or that the category of variants to focus on should be much broader. A review 
by Bodmer and Bonilla in 2008 (38) stated that familial-based studies in complex 
diseases will not have a significant role in finding either rare or common variants 
because of their low penetrance. If that turns out to be the case, we should focus on 
those genes or loci that have already been identified by GWAS and perform gene-
burden association studies for rare variants in very large case-control studies (36).
In conclusion, although we found three linkage regions that segregate with 
celiac disease in this family, the approach we chose might not have been suitable 
for finding the causative variant in this family. We could have missed the causal 
variant(s) simply because our enrichment covered only 30 Mb of the known and 
expressed part of the genome. Current exome-capturing kits cover around 50 Mb. 
It is also possible that true causal variants might be found in the non-coding regions, 
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as suggested by the large number of observed eQTLs for CeD (3), in which case 
whole-genome sequencing rather than a whole-exome approach would be more 
appropriate. Finally, the CeD in this family might be much more complex than we 
imagined and the occurrence of many patients with CeD, in general, could be more 
due to chance than to true co-segregation of “serious” causal variants.
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To the editor,
Ulcerative colitis (UC) is one of the two subtypes of inflammatory bowel 
disease (IBD). UC is a complex genetic disease that involves an abnormal immune 
response to the intestinal microflora causing ulceration of the epithelial barrier of 
the colon. UC symptoms include bloody diarrhoea, anaemia and abdominal pain. 
Twin studies and clustering of IBD in families indicate the presence of genetic factors 
that account for the development of the disease. Genome-wide association studies 
(GWAS) for UC have identified 30 loci with mostly immune-related genes such as 
IL23R, JAK2, STAT3 and IL12B (1). However, these common variants explain only part 
of the heritability due to their low effect size (odds ratios < 2). Part of the missing 
heritability may thus lie in rare causative variants with a larger effect size.
One of the UC associated loci is the IL12B gene, encoding the IL12p40 
homodimer protein produced by monocytes and dendritic cells. IL12p40 is the 
common subunit of two interleukins; IL12 and IL23. IL12 is responsible for T helper 
(Th) 1 differentiation and induces the production of interferon-γ (IFN-γ), whereas 
IL23 is responsible for stabilizing the Th17 phenotype by promoting IL-17 production. 
A common GWAS associated SNP (rs10045431) in IL12B was not associated to UC 
in a Dutch population (2). Hence, we hypothesized that other variants in the IL12B 
gene that were not detected in the replication study due to their low frequency (rare 
variants) or simply because they were not tagged by the replication SNP (due to low 
linkage disequilibrium, LD) might be causative for UC. As expression of cytokines 
is likely to be regulated by variants in their regulatory and coding sequence, we 
genotyped a functional IL12B promoter variant previously associated with two 
other auto-immune diseases, systemic lupus erythematosus (SLE) and asthma 
(3, 4). Further, to search for rare variants, we sequenced the coding part (including 
splice-sites) of the IL12B gene in 350 UC cases of Dutch origin. 
Table 1 shows the genotype distribution, allele frequency and statistics 
of the IL12B promoter polymorphism, an insertion/deletion of 4 bp (rs41292470, 
previously reported as rs17860508), in both a Dutch and a Finnish cohort and in 
a combined analysis. We found moderate association of the GC allele with UC in 
Dutch (OR=0.86; 95% CI: 0.76 – 1.31, P=0.025) whereas in the Finish population 
we observed borderline significant association in the same direction (Table 1). The 
signal became more significant in a combined analysis (OR=0.85; 95% CI: 0.76 – 0.95, 
P=0.003). In the recessive model of inheritance GC/GC genotype was associated 
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with UC in Dutch (OR= 0.77; 95% CI: 0.63-0.93, P=0.008) and combined analysis 
(OR= 0.79; 95% CI: 0.67-0.94, P=0.008). The promoter variant did not appear to be 
in LD with the previously reported GWAS SNP (pair-wise LD statistics (PLINK v1.07, 
r2 0.037 and D’ 0.285), this may explain why this association signal was not identified 
in our earlier replication study (2). 
Different genotypes of the IL12B promoter polymorphism have been linked 
with a broad spectrum of phenotypes. The CTCTAA/CTCTAA insertion genotype 
has been associated with increased mortality in children with cerebral malaria (5). 
Recently, the GC/GC genotype was associated to susceptibility for SLE in a Bulgarian 
cohort (3), whereas the heterozygous genotype has been correlated with severity 
of asthma in children (5). These studies and the present one indicate that genetic 
variation in IL12B plays an important role in the immune response in many diseases 
and the genotype of the promoter variant may influence different phenotypes. 
The IL12B promoter genotype has also been associated with differences 
in IL12 production by stimulated dendritic cells and higher transcriptional activity 
of IL12B (6, 7). In contrast to previous studies, we did not see any correlation 
between the IL12B genotype and IL12 peripheral blood mRNA expression in 350 
Dutch controls (supplementary figure 1). In this new study, we used unstimulated 
cells so it is possible that the IL12b mRNA levels were not high enough to identify 
differential expression. We cannot exclude the possibility of measuring different 
isoforms from the one measured in previous studies. This might happen due to 
different platforms used for the mRNA quantification.
In search of causative rare variants for UC, we sequenced the coding parts, 
including splice sites, of IL12B in 350 Dutch UC cases. We identified four known 
SNPs (two intronic and two non-synonymous, all reported in the dbSNP database) 
and two heterozygous, unknown variants (one nonsense and one splice-site) 
(supplementary figure 2). We have genotyped all the variants in our Dutch UC cohort 
and controls and found very low frequencies of the variants exclusively in UC cases 
(supplementary figure 2). To investigate if there is a significant enrichment of rare 
variants in the UC Dutch cohort, we performed a pooled association test (Fisher’s 
exact test) for rare, potentially functional polymorphisms: the two unknown splice-
site and nonsense variants, and the two known non-synonymous SNPs rs55661460 
and rs3213119. We found no significant association at the allele or genotype level. 
It is possible that we have not genotyped enough individuals and thus do not have 
enough power to find the association. 
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The nonsense mutation reported here (with a frequency of less than 0.05 in 
Dutch UC patients) maps to the functional domain of the IL12B protein and might 
influence the functionality of the protein (supplementary figure 2). The splice-site 
variant maps to a non-conserved site in the splice acceptor site. 
Overall, we found both a very low number of variants, with low frequencies, 
in the Dutch UC cohort (supplementary figure 2), in accordance with Huang et al. 
(8) who sequenced the IL12B gene in 72 individuals and did not find any changes 
that would lead to amino acid substitutions. This suggests that IL12B is a key 
cytokine in which genetic variation is not tolerated. This is further supported by 
the high conservation of IL12B across different species and that IL12B is not under 
evolutionary selection (average integrated haplotype score (iHS) of 0.54 in CEU 
(Utah residents with European ancestry) GWAS SNP rs3212227 iHS -0.20, analyzed 
in 200 Dutch controls) (Haplotter: http://haplotter.uchicago.edu/).
In conclusion, we have shown association of the functional variant in the 
IL12B promoter site with UC. This variant was not tagged by the common variant 
used for replication of the GWAS was thus not picked up in an earlier Dutch cohort 
study. We also identified very rare, nonsense mutations that may influence IL12B 
function. This study shows that although some loci are not replicated, they may still 
be causative and it is therefore important to investigate such loci further. 
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Supplementary figure 1 Peripheral blood mRNA was collected from 450 control individuals using 
PAXgene tubes (Qiagen). Starting with 200 ng of RNA, the Ambion Illumina TotalPrep Amplification Kit 
was used for anti-sense RNA synthesis, amplification, and purification, according to the manufacturer’s 
protocol (Applied Biosystems/Ambion, Austin, TX, USA).750 ng of complementary RNA was hybridized 
to Illumina HumanHT12 BeadChips (Illumina, San Diego, CA, USA) and scanned on the Illumina 
BeadArray Reader. Data were quantile-quantile normalized per tissue using Genespring GX software 
(Agilent technologies). Differences in IL12B gene expression according to promoter genotype were 
calculated using one-way ANOVA. 
Supplementary figure 2. Variants identified through Sanger sequencing (*) and further genotyped 
(**) in the Dutch (750 cases, 750 controls***) and Finnish (318 cases, 299 controls***) cohorts. The 
protein and genomic location is shown for each variant. The frequencies for the variants in the Dutch 
cases and controls are shown in brackets. These variants were not found in the Finnish cohort.
NF: variant was not followed by genotyping.
(*) Sanger sequencing: The PCR reaction was performed with 50 ng genomic DNA. The primers used 
and conditions of the PCR reaction are available upon request. Sequences were read on a 3730 DNA 
analyzer and 3130 Genetic analyzer (Applied Biosystems, Foster City, CA, USA;
www.appliedbiosystems.com). Sequences were analyzed using ContigExpress software (Invitrogen, 
Carlsbad, CA) and GeneMapper 4.0 (Applied Biosystems).
(**) Variants were genotyped on 5 ng DNA using TaqMan chemistry assays from Applied Biosystems 
using a standard protocol provided by them. The PCR assays and allelic discrimination were run using 
an ABI PRISM 7900HT Sequence Detection System instrument (Applied Biosystems). Data was analyzed 
using the SDS program 2.3 (Applied Biosystems).DNA was isolated from peripheral blood samples 
using standard laboratory procedures.Concentrations and purity were determined with NanoDrop 
ND-1000 (Isogen Life Science, De Meern, the Netherlands). 
































Supplementary figure 1. IL12B mRNA expression according to IL12B promoter genotype
Peripheral blood mRNA was collected from 450 control individuals using PAXgene tubes (Qiagen). Starting with 200 ng 
of RNA, the Ambion Illumina TotalPrep Amplification Kit was used for anti-sense RNA synthesis, amplification, and 
purification, according to the manufacturer's protocol (Applied Biosystems/Ambion, Austin, TX, USA).
750 ng of complementary RNA was hybridized to Illumina HumanHT12 BeadChips (Illumina, San Diego, CA, USA) and 
scanned on the Illumina BeadArray Reader. 
Data were quantile-quantile normalized per tissue using Genespring GX software (Agilent technologies). 
Differences in IL12B gene expression according to promoter genotype were calculated using one-way ANOVA. 
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Supplementary figure 1. Variants identified through Sanger sequencing (*) and further genotyped (**) 
in the Dutch (750 cases, 750 controls***) and Finnish (318 cases, 299 controls***) cohorts.  
The protein and genomic location is shown for each variant. The frequencies for the variants in the 
Dutch cases and controls are shown in brackets. These va iants were not found in th  Finnish cohort. 
NF: variant was not followed by genotyping.  
 
(*) Sanger sequencing: The PCR reaction was performed with 50 ng genomic DNA. The primers used 
and conditions of the PCR reaction are available upon request. Sequences were read on a 3730 DNA 
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Abstract
Genome-wide association studies (GWAS) in coeliac disease have shown strong 
and replicable association to 26 non-HLA loci in individuals of European descent. 
Since coeliac disease is equally prevalent in northern India, we aimed to assess 
association to these 26 risk loci in a north Indian population and to see whether 
dense SNP genotyping in both populations could help refine the association signals. 
We first performed cross-ethnic mapping in 497 coeliac disease patients and 
736 controls from northern India and in 1,150 Dutch cases and 1,173 controls; 
we used Immunochip, a customized genotyping platform providing a higher 
SNP resolution for immune-related traits than standard GWAS platforms. Due to 
differences in linkage disequilibrium (LD) structure between Europeans and north 
Indians, we applied two different strategies which led to replication of 50% of the 
non-HLA loci. In an ‘exact’ analysis – directly testing for association of the index SNP 
– we replicated five loci, whereas in a ‘transferability’ analysis – testing the exact 
European SNP along with the variants in LD – we replicated 12 loci. The use of the 
densely probed Immunochip increased the replication rate by 15% compared to a 
standard GWAS platform. Secondly, we narrowed down the association signals by 
using a cross-population analysis. We observed that the northern Indian population 
was characterized by less extensive long-range LD than our Dutch population. For 
five of the 26 non-HLA loci, this resulted in a finer localization of the association 
signal and for another five loci we observed a shift in the association signal. It was 
particularly notable that the long-range LD was broken down at the IL2/IL21 locus 
(592 kb) and we were able to localize the association signal to a small interval of 
21 kb, near the promoter region of the KIAA1109 gene.
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Author summary 
 Most disease-gene mapping approaches have been conducted in 
populations of European descent. It is unclear how many of these findings can be 
translated across different racial or ethnic groups: Are the risk alleles the same? Are 
the effects of associated alleles comparable? How comparable are the localization 
signals? Fine-mapping is one way to better localize the signals and thereby bring us 
closer to translational studies and a practical application of genetic findings. Cross-
ethnic mapping in distinct populations has the potential to aid such fine-mapping 
efforts. We applied this strategy to fine-map 26 non-HLA loci associated to coeliac 
disease in Europeans. For the first time, we used dense genotyping information 
from a custom-made platform to elucidate the best possible linkage disequilibrium 
resolution. We replicated 50% of these risk loci in a northern Indian cohort. For five 
of the regions, the signals from the north Indian population clustered separately 
from those in Europeans, which allowed us to refine the association signal. In 
five other loci, we were able to narrow down the association to a smaller genetic 
interval, covering a cluster of correlated markers. This indicates that we may have 
identified regions likely to capture the causative variants.
Introduction
Over the past five years, genome-wide association studies (GWAS) have 
had tremendous success in mapping genetic loci for common, complex diseases. 
To date, more than 4,000 SNPs have been reported to be associated with the 
risk for more than 400 distinct traits (1). Approximately 180 common variants, all 
with modest effect sizes, have been established for immune-mediated diseases 
and many more variants are expected to be identified to account for part of the 
“hidden heritability”. The great majority of GWAS for immune-related diseases have 
been conducted in populations of European ancestry and it is likely that further 
risk alleles may be identified in populations with different ethnic backgrounds (2). 
However, knowledge of the genetic architecture of common complex diseases 
across multi-ethnic cohorts is rather limited and there is a clear need to replicate 
disease associations across different ethnicities. A limited number of recent 
GWAS and replication studies in multi-ethnic cohorts, including African and Asian 
populations, suggest that Caucasian association signals can be generalized to 
populations with other ethnic backgrounds (3-5). On the other hand, 25-55% of the 
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association signals at shared loci are independent between populations, suggesting 
that disease aetiology is common between populations but that risk variants are 
often population-specific (6). This observation has consequences for the design of 
cross-ethnicity replication studies.
 Replication studies in ethnically different populations often attempt to 
replicate only the reported, and therefore most significant, SNP from a certain 
study or combined meta-analysis. Given the difference in linkage disequilibrium 
(LD) structure between distinct ethnic groups, such an approach may fail if this 
top-SNP ‘poorly’ tags the true risk variant in another population. Alternatively, the 
most significant and reported SNP, together with SNPs in LD with it, can be tested 
in additional and ethnically different samples (7). One obstacle is, however, that 
the available GWAS platforms have been designed to capture genetic variation in 
populations of Caucasian descent and have less power for other ethnic groups. We 
aimed to overcome some of these limitations by performing a cross-ethnic study 
using the most densely probed platform for immune-related diseases available, the 
so-called Immunochip platform. 
Coeliac disease is an autoimmune inflammatory disease of the small 
intestine, caused by consumption of gluten by genetically predisposed individuals. 
It is the most common form of intestinal inflammatory disorder among Europeans 
with 1-3% prevalence (8), and a similar 1% prevalence in the northern part of 
India (9). The largest genetic risk to coeliac disease is conferred by variants in HLA 
genes, which account for approximately 35-40% of the genetic risk (10). Recent 
progress in understanding the genetic architecture of coeliac disease has led to the 
identification of 26 non-HLA loci in a meta-analysis of British, Dutch, Italian and 
Finnish populations, with replication in further cohorts of European origin (10).
 In this study, we focused on the 26 established, non-HLA, coeliac disease 
loci and assessed their replication in a north Indian population-based sample of 
497 patients and 736 unrelated controls. We combined our replication study with fine-
mapping, as we used information on 15,851 SNPs across the 26 loci (i.e. on average 
610 SNPs per locus) which were present on the Immunochip. The Immunochip is 
a custom-made genotyping platform with ~200,000 markers, of which the great 
majority map within the 183 loci associated to immune-related diseases (11, 12). 
This platform was specifically designed to fine-map currently known GWAS loci and 
results with, on average, a 12-15x greater marker density than a standard GWAS chip. 
Aszperl_ProofPrint.indd   100 28-07-2012   00:55:20
Chapter VI Cross-ethnic replication and fine-mapping of coeliac disease loci
101
We applied two different strategies to assess the genetic architecture of 
coeliac disease in the north Indian population: (1) an ‘exact’ analysis, directly testing 
the index top-associated SNP reported for Europeans, and (2) a ‘transferability’ 
analysis, testing the exact European SNP along with the variants in LD (r2 > 0.05) 
which were present on the Immunochip. Our main objectives were to evaluate 
the known coeliac disease-associated loci in an ethnically distinct north Indian 
population, and to refine the association signals. Using these approaches, we 
convincingly replicated 13 of the 26 loci (50%). Had we tested only the reported 
European variant using the ‘exact’ approach, the replication success rate would have 
been only 19%. We further performed the cross-ethnic fine-mapping by comparing 
LD structures between the north Indian and Dutch cohorts, followed by haplotype 
sharing analysis for all 12 transferable loci. We were able to fine map one of the risk 
haplotypes of the IL2/IL21 locus, mapping it to a smaller interval near the promoter 
region of the KIAA1109 gene.
Materials and Methods
Ethical Statement
 Ethical approval for this study was granted by the respective institutional 
and university ethical committees. Informed written consent was acquired from all 
participants. 
Study Populations
 We analyzed two distinct populations: a north Indian and a Dutch 
population. North Indian patients were recruited from Dayanand Medical College 
and Hospital, Ludhiana, Punjab, northern India. North Indian controls included 
blood donors recruited from the same region as the cases and who tested negative 
for coeliac disease serology. Dutch cases were recruited from University Medical 
Centre Utrecht, Leiden University Medical Centre, and VU Medical Centre, 
Amsterdam. A small proportion of samples was recruited via the Dutch patients’ 
society (‘Glutenonderzoek’). Coeliac disease patients were diagnosed according 
to standard clinical, serological and histopathological criteria, including a small 
intestinal biopsy. The majority of samples included in this study have been described 
in detail elsewhere (12).
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DNA Extraction and Genotyping
 The great majority of DNA samples came from blood, while a small proportion 
of Dutch cases and controls were derived from saliva. Samples were hybridized on 
the Immunochip, a custom-made Infinium chip with 196,524 markers. Genotyping 
was carried out according to Illumina’s protocol at the genotyping facility, University 
Medical Centre Groningen. NCBI assembly hg18 was used to map to the genome 
(Illumina manifest file Immuno_BeadChip_11419691_B.bpm). 
Genotype Data Quality Control
 We required samples to have a 98% call rate based on the 172,242 high 
quality, manually clustered SNPs. Individuals showing high relatedness (PI_HAT 
> 0.2), or discordant sex were removed. Markers with significant deviation from 
Hardy-Weinberg equilibrium (p > 10-3) or a per-SNP call rate < 99% were removed 
from the final dataset. 
 Population outliers were identified by multi-dimensional scaling (MDS 
implemented in PLINK (20)) on 11,192 SNPs that were common (MAF > 0.05), 
LD pruned (a window of 1000 variants, sliding by 10 SNPs at a pair-wise SNP-SNP 
correlation r2 = 0.05) and shared between Immunochip and HapMap3 samples. 
MDS analysis was performed jointly with HapMap GIH (Gujarati Indians in Houston, 
Texas), CEU (Utah residents with Northern and Western European ancestry from the 
CEPH collection), YRI (Yoruba in Ibadan, Nigeria) and CHB (Han Chinese in Beijing, 
China) samples to identify major population outliers and also locally. Local analysis 
was performed separately for Dutch and Indians, to ensure the cases-controls were 
matching. All outlying samples were excluded from the analysis. 
 Immunochip contains 3016 variants submitted for the replication of the 
‘Reading and math skills’ GWAS. As these SNPs are unlikely to be confounded by 
the immunity signal (49 SNPs mapping within HLA were excluded), we used this SNP 
set as a null reference for calculating genomic inflation.
Statistical Analysis
 Logistic regression was performed using PLINK v1.07 (20). Because we 
observed population substructure in the north Indian cohort, the north Indian 
association test was corrected for this by including the first three components of 
the MDS analysis as covariates in the logistic regression. For both cohorts, gender 
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was included as a covariate in the logistic regression. 26 non-HLA loci, associated 
with coeliac disease at genome-wide significance level (10), were the focus of this 
study. We employed two strategies to test for replication of European signals in 
Indians.
 Exact replication tested for association signals (p ≤ 0.05) among the 26 index 
SNPs from Dubois et al. (10) (Table S1). Two of the index SNPs were not present on 
Immunochip and were replaced with their best proxy; within the IL18RAP locus, 
rs917997 was replaced by rs7559479 (r2 = 1) and within the ITGA4/UBE2E3 locus, 
rs13010713 by rs1018326 (r2 = 0.9). 
 Transferability of European signals in Indians was assessed by extracting 
all correlated markers, measured by r2 > 0.05 (21) between the index SNP and all 
variants present within coeliac loci in CEU (from 1000 Genomes data). LD boundaries 
were defined by extending 0.1 cM to the left and right of the European focal SNP as 
defined by the HapMap3 recombination map (reported in Dubois et al. 2010 (10)). 
We then mapped the transferable variants to Immunochip and required at least 
one variant per locus at p < 0.01 to replicate the European signal. The SNP tagging 
ICOSLG locus was not present in the 1000 Genomes data, so we used rs2838531 
from HapMap3, a perfect proxy (r2 = 1).
 To assess the rate of transferability expected by chance, we permuted case-
control labels and mapped the transferable SNPs into the permuted data. For 1000 
permutations, 31 loci transferred at p < 0.01.
 Genotype clusters for all the significant markers identified by any of the 
three approaches were manually inspected in GenomeStudio.
CROSS Test
Risk haplotypes were established by performing segmental sharing (CROSS 
test (13)) followed by the association test in PLINK (20). Previously published 
boundaries of the coeliac disease loci (10) were used and extended by an extra 
100 SNPs both upstream and downstream of the locus. We further performed the 
segmental sharing with the CROSS test, where the longest shared segment between 
cases versus controls was established after conditioning on each of the SNPs. We 
considered the results from the CROSS test as significant if the CROSS-p value was 
lower than the p-value cut-off calculated (separately for each of the loci) as the 
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Bonferroni corrected value. By conditioning on each of the SNPs in the locus we 
could investigate its effect on association of the haplotype and select only those 
SNPs that drove it. Finally, we plotted p-values (single SNP logistic regression test) 
for each of the SNPs against the CROSS p-value to select candidate segments built 
up from the SNPs which drive association of the haplotype and which are also 
strongly associated to the disease (Figure 3 and Supplementary figure 9). Selected 
in this way, the SNPs are highly likely to include the causative variant or to tag it 
effectively, creating the risk haplotype. If haplotypes within and between sets show 
similar sharing conditional on genotypes, it means that there is no evidence for 
the presence of variation not in strong LD with the SNP’s on which conditioning 
takes place. Simulation tests (not shown here) have shown that when haplotypes 
span many adjacent loci, phasing genotypes into haplotypes does not improve 
power. SNPs clustering tightly together were therefore selected for phasing 
(creating haplotypes) and haplotypes were tested for association using PLINK (20) 
in each population. To investigate whether the risk haplotypes in the Indian and 
Dutch populations cluster together, we used the maximum likelihood method 
implemented in MEGA 5 (22).
GWAS and 1000 Genomes Data
 We used previously published coeliac disease GWAS data (10) (Illumina 
Human Hap550 platform) and extracted 1,284 SNPs mapping in the 26 coeliac loci 
and shared with Immunochip. To assess the transferability rate we followed the 
same analysis flow as for the Immunochip data.
 To estimate the coverage of the genetic variation within coeliac disease loci 
we used 1000 Genomes data (23) (May 2011, SNP calling) and extracted all the 
annotated variants present in the sequenced samples of European descent: CEU 
(CEPH individuals), TSI (Tuscan individuals, Italy), FIN (HapMap Finnish individuals 
from Finland) and GBR (British individuals from England and Scotland). The May 
release of 1000 Genomes did not include any samples of Indian origin.
Test of Heterogeneity
 The homogeneity of ORs between Dutch and Indian cohorts was assessed 
by the Breslow-Day test. To estimate an accurate significance threshold for this 
test we permuted the disease status labels in both cohorts and calculated the 5% 
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quantile of the nominal p-value distribution of Breslow-Day test statistics for 15,851 
polymorphic variants in 26 coeliac loci among 1000 permutations.
Comparative LD Background Evaluation
 For 11 transferable loci we visualized the LD structure for the entire region 
in Indian and Dutch controls using Haploview v4.2 (24). No minor allele pruning was 
performed to get an accurate account of the cross-population LD differences. In all 
but three loci, we used all 736 north Indian controls and 1,150 Dutch controls. Due 
to computational limitations for the CCR1/5, IL2-IL21 and ITGA4/UBE2E3 loci, we 
used 400 random controls from each population.
Estimation of Fixation Index (Fst)
A pair-wise fixation index (25) was calculated for all 12 European index SNPs. 
We used a control dataset from Indian, Netherlands, UK, Polish, Italian and Spanish 
populations. We calculated the significance level at Fst = 0.079 based on the upper 
5th percentile of Fst distribution for 8,007 ‘neutral’ SNPs. We determined neutral 
SNPs as intronic and uncorrelated with the coding variants (pair-wise r2 = 0.05).
Software and Resources
 Raw genotype data was processed with GenomeStudio_v2010.3. Statistical 
analysis and quality control was performed with PLINK v1.07 (http://pngu.mgh.
harvard.edu/~purcell/plink/). Plots were generated in R (http://www.r-project.
org/). Haploview v4.2 was used to visualize LD plots. 1000 Genomes data was 
retrieved from http://www.1000genomes.org/. World-wide allele frequency 
distribution data was taken from (http://hgdp.uchicago.edu/).
Results
We obtained high quality genotype data for 160,448 polymorphic variants 
that were common in 497 north Indian coeliac disease cases and 736 controls, and 
in 1,150 Dutch coeliac disease cases and 1,173 controls. The first three components 
of multi-dimensional scaling analysis (MDS) showed that the north Indian samples 
overlapped with the GIH samples from HapMap3 (Gujarati Indians in Houston, 
Texas) (Supplamentary figure 1). However, the analysis of GIH and our north 
Indian samples indicated subtle population substructures. The second component 
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separated the north Indian samples from the GIH samples, while the third 
component identified further gradients in both these populations. The fact that the 
first and third components seemed to extract similar information from both the 
GIH and our cohort indicates that the bias is not due to our cohort sampling but is a 
genetic characteristic of this ethnic population. 
After stringent quality control (see Material and Methods), we obtained 
17,979 SNPs mapping within the 26 non-HLA loci, 15,851 of which were polymorphic 
in at least the north Indian or the Dutch cohort and therefore informative for further 
analysis. Of the set of 15,851 SNPs, 8,664 (54.7%) were variants with a low minor 
allele frequency (MAF < 0.05) in the north Indians and 8,484 (53.5%) in the Dutch.
Replicating European Signals in North Indian Cohort
As expected, we observed strong association of the north Indian coeliac 
disease cases to the HLA region (rs2854275, p = 2.634-49). We observed strong 
inflation in the test statistics among all Immunochip variants (λ = 2.91), which is 
mainly driven by the HLA locus (Figure 1A) as exclusion of the HLA region SNPs 
reduced the λ to 1.04 (Figure 1B). The Immunochip is preselected for “immune” 
SNPs, therefore it is difficult to distinguish enrichment of true signals from population 
stratification. When we used the 2,626 ‘null variants’ present on the Immunochip as 
a replication of ‘reading and writing skills’ GWAS (see Materials and Methods), we 
noted that there was no inflation (λ = 1.01), implying that the observed associations 
were not confounded by population substructure (Figure 1C). We observed a clear 
indication of association for the 15,851 SNPs residing in the 26 non-HLA coeliac 
disease loci (λ = 1.27, Figure 1D).
 The initial association of coeliac disease to the 26 non-HLA loci, all of 
which have modest effects on the genetic risk (OR (odds ratio) of 0.74 -1.36), was 
performed in a sample size of over 5,000 coeliac cases and 10,000 controls (10). We 
realize that our north Indian cohort was underpowered to detect associations with 
small effects although we did reach 80% power for common SNPs (MAF > 0.25) and 
OR > 1.3 (Supplementary figure 2). 
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Figure 1. Inflation in test statistics for all Immunochip variants. We observed strong inflation in the 
test statistics for all the Immunochip variants when including the HLA region (λ = 2.91; panel A). This 
inflation decreased to λ = 1.04 after excluding some 10,000 markers from the HLA locus, a strong, 
well-known genetic risk factor for coeliac disease (panel B). The SNPs submitted for replication of the 
‘reading and math skills’ were used as ‘null’ variants not confounded by the immune signal, to test for 
population stratification in our north Indian cohort (λ of 1.01; panel C). Variants in the 26 non-HLA, 
coeliac disease loci were strongly enriched for association signals (panel D). 
‘Exact’ Analysis
For the ‘exact’ analysis we aimed to test the same top-associated SNPs 
reported for Europeans (the ‘index’ SNPs), as described by Dubois et al., (10), in 
our north Indian cohort. All of the 26 European index SNPs were polymorphic 
and frequent (MAF > 0.05) in north Indians, although the correlation of the minor 
allele frequencies for these 26 index SNPs between the north Indians and Dutch 
was much lower (r2 = 0.35) than the correlation between European cohorts (mean 
r2 = 0.9) (Supplementary figure 3). Of the 26 index SNPs, five were directly replicated at 
p < 0.05, with the same direction as in Europeans (Table S1). The five SNPs tagged the 
following genes: IL12A (rs17810546, p = 0.02), LPP (rs1464510, p = 0.048), THEMIS/
PTPRK (rs802734, p = 0.047), ZMIZ1 (rs1250552, p = 0.04) and ICOSLG (rs4819388, 
p = 0.035) loci. Of the remaining 21 Indian variants that did not reach the replication 
significance threshold, 14 (66%) showed the same directionality as in Europeans, 
which is more than the 50% chance expected under the null hypothesis (p = 0.05, 
binomial probability, we excluded two loci for which OR was 1) (Supplementary 
figure 4). 
Chapter 6 Figure 1
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‘Transferability’ Analysis 
We next performed an analysis that accounts for the different LD patterns 
between Europeans and north Indians. In this we tested all the variants in each 
of the 26 non-HLA loci that were in LD with the top SNP (r2 > 0.05, based on CEU, 
1000 Genomes Project). To claim a locus as ‘transferable’, at least one SNP per 
locus had to be associated at p < 0.01 in our north Indian sample. Twelve of the 
26 loci were transferable to Indians, which was significantly more than expected 
by chance (ppermuted = 0.031). These were: PLEK, IL18RAP, ITGA4/UBE2E3, CCR1/5, 
IL12A, IL/IL21, THEMIS/PTPRK, TNFAIP3, TAGAP, ZMIZ1, ETS1 and ICOSLG (Table 
1); the IL12A, THEMIS/PTPRK, ZMIZ1 and ICOSLG loci were also identified by the 
‘exact’ analysis. None of the transferable variants demonstrated significant cross-
population heterogeneity between north Indians and the Dutch (Breslow-Day 
ppermuted < 1.27x10
-5). See Table S2 for details of the non-transferred loci.
Coverage and Transferability Rate
To investigate how much we gained by using a dense genotyping platform in 
contrast to a standard GWAS chip, we calculated the transferability success rate of 
the 1,284 SNPs that map within the 26 coeliac disease loci that are shared between 
the Illumina Hap550 platform and Immunochip. We replicated nine loci at p < 0.01, 
yielding a 35% success rate compared to 50% when using the Immunochip (Table S3).
 The transferability rate is strongly influenced by the actual coverage of the 
genetic variation. We therefore assessed how well the Immunochip covers total 
variation at coeliac disease loci in the 1000 Genomes European samples. There 
are 26,863 polymorphic variants annotated within coeliac disease loci in CEU, TSI, 
FIN and GBR individuals; 12,497 (46%) of these are shared with Immunochip SNPs 
(821 were non-polymorphic in either the Indians or Dutch). 648 SNPs genotyped 
on Immunochip were not present in the 1000 Genomes data. 5,632 (39%) variants 
of the non-genotyped 1000 Genomes variants (14,366) contribute to the common 
variation in Europeans (MAF > 0.1). The remaining variation is of low frequency (MAF 
< 0.05, Supplementary figure 5), and it is likely that these are largely population-
specific or falsely called sequence variants.
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Figure 2. Examples of cross-ethnic mapping results. A) Shifted and more localized association signal 
in the north Indian samples compared to the Dutch association. Note that the association signal in 
the smaller Indian samples is stronger than in the Dutch samples, suggesting that some loci may have 
stronger effects in one population than the other. PLEK is also a locus for which we observed positive 
selection pressure. B) A cluster of correlated variants localizes in the intronic region of THEMIS gene, 
whereas the Dutch signal maps 124 kb upstream, pointing towards the 3’UTR of the PTPRK gene. At 
this locus the index SNP was successfully replicated in north Indians (P < 0.05). C) Overlapping signal 
between the Dutch and north Indians, with tighter SNP clustering over a 21 kb block in north Indians, 
compared to the dispersed association over a 103 kb block in the Dutch. D) The overlapping signal 
between the two populations is broadly spread across the region. However, in north Indians a cluster 
of correlated SNPs localizes in the small 21 kb LD block. Note the LD breakage in north Indians due to 
the larger number of low frequency SNPs (MAF < 0.1), which results in two smaller LD blocks. 
Dark blue represents the association signal in the north Indian samples and grey in the Dutch. Dark 
green depicts the most associated transferable SNP, and light green the SNPs strongly correlated with 
it (r2 > 0.08). Yellow depicts all the transferable SNPs and red indicates the index SNP. Colours may 
overlap. 
Chapter 6 Figure 2 
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Cross-Population LD Measure
To assess if the north Indian transferability signals reflect European 
associations, we estimated the degree of LD correlation (quantified by pair-wise 
SNP LD, r2) between the European index SNP and the north Indian top transferable 
SNP in CEU and north Indian data. We observed that the north Indian transferable 
signals reflected the European LD (correlation coefficient r2 = 0.83) (Supplementary 
figure 6A). However, the majority of the transferable signals accumulated in the 
lower tail of r2 values, with a small shift towards less tight LD in north Indians than 
in the CEU population. 
We also evaluated the LD correlation between all transferable variants (all 
SNPs in r2 > 0.05 based on CEU, 1000 Genomes data, and present in north Indians) 
and the top SNP (Supplementary figure 6B). We observed similar results, although 
the LD correlation between CEU and Indians was lower (r2 = 0.55), and most of 
the transferable variants were located in the lower tail of r2 values. We therefore 
concluded that although north Indians reflect the European association signals, the 
LD structure at coeliac loci differs substantially between these populations.
Contrasting Association Signals
As a consequence of longer LD blocks, associations in Europeans often map 
to regions containing multiple genes and because of the strong LD, it can be difficult 
to pinpoint the true risk gene. Using ethnically distinct populations offers the 
opportunity to fine-map signals because of population differences in LD structure.
 From the 13 loci that were replicated in north Indians, we excluded the LPP 
locus because it was only replicated by the direct SNP test. We then compared the 
overlap of the association signal patterns between north Indians and the Dutch and 
evaluated the LD structure (Supplementary figure 7). Five loci showed a shift in the 
association pattern (PLEK, ITGA4/UBE2E3, THEMIS/PTPRK, TAGAP and ICOSLG). At 
2p14 (PLEK locus) the Dutch signal spreads over the middle LD block and covers the 
PLEK gene, whereas the north Indian signal locates at 69 kb from the European top 
SNP, downstream of this gene (Figure 2A, Supplementary figure 7). The north Indian 
signal is located in a block of low LD and is poorly correlated with the European 
index signal. At the 6q22.33 (THEMIS/PTPRK locus) we observed a cluster of 
correlated variants in the intronic region of the THEMIS gene. However, the Dutch 
signal at this locus maps 124 kb upstream, clearly pointing towards the 3’UTR of the 
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Figure 3. CROSS test results at 
IL2/IL21 locus. 
(A) The left panel compares 
the association signals of the 
CROSS test (green dots) and 
the single SNP associations 
(red crosses). In Indians, a 
clearly stronger signal is pres-
ent in the first part of the locus 
and identified by both meth-
ods. In the Dutch samples, 
the stronger association in the 
first part of the region is only 
observed with the CROSS test, 
indicating its higher sensitiv-
ity. The right panel presents 
CROSS association results 
against the single SNP asso-
ciation. SNPs that are highly 
significantly associated in the 
single SNP analysis and at the 
same time close to zero on the 
pCROSS scale are of interest 
(meaning the SNP has a strong 
effect on the haplotype and 
upon conditioning on it, the 
association of the haplotype is 
significantly decreased). SNPs 
selected by this method were 
further used for haplotype 
reconstruction (marked in 
circles). In the Dutch popula-
tion we observed two clusters, 
resulting in two haplotypes. 
Both scales are logarithmic. 
(B) Based on the SNPs selected 
from CROSS test super-haplo-
types were constructed and 
tested for association. Super-
haplotypes were created by 
merging all SNPs that were se-
lected from both populations. 
Orange colour represents risk 
alleles specific for the single 
population, whereas in green 
are the risk alleles which were 
selected from the other popu-
lation. Only SNPs from the 
second cluster in the Dutch 
population were included in 
the construction of the super-
haplotypes (panel A, SNPs in 
blue circle). 
(C) Phylogenetic analysis of 
the haplotypes. Orange indi-
cates risk allele and green the 
protective allele. Stars indi-
cate the two most associated 
haplotypes in north Indians 
(IN) and the Dutch (NL). 
Chapter 6 Figure 3 
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PTPRK gene (Figure 2B; a detailed description of all loci is given in Supplementary figure 7). 
At another five loci (IL18RAP, CCR1/5, IL12A, IL2/IL21 and ETS1), the 
pattern of association in north Indians was consistent with that seen in the Dutch. 
Nonetheless, for some loci, the association signal could indeed be refined to a 
smaller region. At the ETS1 locus, the LD architecture is very similar between 
the Dutch and north Indians and the cross-population signals overlap (Figure 2C, 
Supplementary figure 7). However, the north Indian signal is much more tightly 
clustered in proximity to the top European SNP (21 kb block, from 127882690 bp 
to 127904148 bp), whereas the Dutch signal is widely spread (over a 103 kb region 
from 127882690 bp to 127985506 bp). The coeliac disease region at chromosome 
4q27 harbours four genes, including two plausible candidates for coeliac disease, IL2 
and IL21. Due to the strong LD across the locus, the signal cannot be further refined 
in Europeans. However, in our north Indian cohort, the LD was broken down due to 
the larger number of low frequency SNPs (MAF < 0.1) (Figure 2D, Supplementary 
figure 7). These result in two smaller LD blocks in north Indians, compared with one 
large block in the Dutch (Supplementary figure 8D). The association signal was also 
spread along the whole region, although an outstanding cluster of most strongly 
associated SNPs was located in the small 21 kb block (123246379 bp - 123267309 
bp) adjacent to the large block that covers the KIAA1109 gene and the top European 
SNP. 
At the TNFAIP3 and ZMIZ1 loci, only a single SNP was transferable, hence it 
was not possible to deduce the association patterns. 
Cross Ethnic Fine-Mapping using CROSS Test and Construction of Risk Haplotypes 
 In order to fine map loci replicating in north Indians, we performed haplotype 
sharing analysis using the CROSS (13) test followed by the haplotype association 
test. The CROSS test is more sensitive than a single SNP association test as apart 
from single SNP information, it also incorporates information on haplotype sharing. 
In short, the CROSS tests if the case and control haplotypes show significantly less 
sharing than two random haplotypes. The significance for our CROSS analysis was 
defined by a Bonferroni correction based on LD pruned SNPs (r2 < 0.05) for each locus 
separately. Three of 13 loci in the CROSS test (we focused on the loci replicating in 
north Indians) reached the significance threshold in both north Indians and Dutch 
population: IL2/IL21, IL12A and THEMIS/PTPRK (Figures 3 and S9).
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The conditional CROSS test (available from NBIC in an integrated package) 
compares, using a phenotype randomization test, the agreement between two 
datasets with the agreement within the two datasets, measured as the number 
of possible common haplotypes. Possible common haplotypes are defined as the 
number of markers between the two closest loci with opposite homozygosity. 
Phasing is therefore eliminated. The comparison is made conditional on the 
genotypes at a specific locus. If the within set agreement is equal to the between 
set agreement, the possible shared haplotypes are equal. This test is independent of 
association. Ideally the most significantly associated SNP should show no difference 
in the conditional CROSS test, but adjacent linked loci should. If there are multiple 
causal SNPs, no zero CROSS result is expected. A zero CROSS result coinciding 
with maximum single SNP association is therefore likely caused by a causal SNP 
or a SNP in strong LD with a causal SNP (Figures 3 and S9). Further, based on this 
SNP selection, we constructed haplotypes which were then tested for association 
(referred to as CROSS haplotypes in Table S5).
IL2/IL21 was the most successfully fine-mapped locus. It is characterised 
by a very strong LD in European populations, resulting in the SNP association signal 
spreading throughout the whole locus in the Dutch population. However, in the 
north Indians this association is limited to only a small 21 kb region and the pattern 
of SNP association is mirrored by the CROSS association. This is not the case in 
the Dutch population where the SNP association covers the whole locus, but the 
CROSS test is more sensitive and depicts stronger signal overlapping with the north 
Indians. In the north Indian population, the only risk haplotype (Indian_CROSS: 
OR = 1.53, p = 0.000562) mapped to the first part of the locus (123236177 bp 
to 123246319 bp) (Figure 3,Table S5). In the Dutch population we observed two 
haplotypes, reflected by two clusters of SNPs when we plotted the CROSS results 
versus single SNP association (Figure 3). The first cluster of SNPs constructed a 
risk haplotype (OR = 1.36, p = 0.000202) comprising 12 SNPs scattered through 
the entire locus. The second cluster (OR = 1.27, p = 0.000432) was made up of 
15 SNPs, seven of which overlapped with those in the north Indians, indicating 
it was the same risk haplotype. Of 15 SNPs, 12 clustered tightly in the small, 
41 kb interval (123204083 bp – 123245876 bp). However, three SNPs were located 
downstream from this cluster, scattering over the locus and reflecting the high LD 
structure in the region. We constructed a super-haplotype, which comprised SNPs 
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present in the Dutch and north Indians, and resulted in 16 SNPs (Table S5). The 
super-haplotype was then separately tested for association in both populations. 
The most associated risk super-haplotype, #Dutch_9 (OR = 1.26, p = 0.00238), was 
a comparable risk to the Dutch_CROSS haplotype (OR = 1.27, p = 0.000432). In the 
north Indians the most associated super-haplotype, #India_13, showed a lesser 
degree of association but a higher risk compared to the CROSS haplotype (OR = 1.8 
and p = 0.0047 compared to OR = 1.53, p = 0.000562, respectively) (Table S5). Both 
the identified risk haplotypes, #Indian_13 and #Dutch_9, included the risk allele 
of the top transferable north Indian SNP rs6534338*T (imm_4_123246319*T). The 
CROSS test therefore confirmed the localization of the association signal upstream 
of KIAA1109, which had been identified by the transferability approach. In the 
phylogenetic analysis, #India_13 and #Dutch_9 clustered in the neighbourhood, 
indicating the same common ancestor. 
Evaluation of the Selection Pressure
To understand evolutionary variability at the 26 coeliac disease loci, we 
estimated a pair-wise fixation index (Fst) using the north Indian and Dutch cohorts. 
We tested Fst for all 26 reported index SNPs (Table S4). We found suggestive evidence 
of positive selection pressure for four previously reported loci: IL18RAP (rs7559479), 
CCR1/5 (rs13098911), PLEK (rs17035378) and SH2B3 (rs653178) (Fst>0.079). 
Discussion
Recent cross-ethnic studies indicate that a large proportion of disease- or trait-
associated common variants established in populations of European descent also 
contribute to the risk in other ethnic group (3, 4, 14). Yet this observation cannot 
be generalized because only a few of the GWAS were conducted in non-European 
populations (15). We sought to replicate and narrow down coeliac disease loci 
associated in Europeans in a north Indian cohort. We used the Immunochip platform 
to capture the differences in genetic background between two ethnically distinct 
populations efficiently. This is the genotyping platform that, at present, offers the 
highest coverage of regions associated to immune-related disorders. We directly 
tested for association of the top European SNP (exact test) and also performed 
association of the ‘index’ SNP together with variants in LD with it (‘transferability’ 
test). Of the 26 coeliac disease loci established in Europeans, five were replicated by 
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the exact index SNP association analysis and 12 were replicated by the transferability 
approach, yielding a total of 13 unique, replicated loci. Overall, our replication 
success rate was 50%, compared to the 19% that we would have obtained by testing 
only the European index SNP. When investigating the LD correlation between index 
SNPs and transferable markers, we noticed a trend towards a lower range of r2 values 
in north Indians than in the Dutch (Supplementary figure 6). This indicates a lesser 
degree of tagging properties between the index SNP and transferable markers in 
north Indians, which could have negatively influenced our replication success rate.
 We observed an advantage of using the Immunochip over a standard 
GWAS platform, with a 50% versus 35% successful transferability rate. Nonetheless, 
despite the high marker density, we estimate that the Immunochip only covers 
approximately 50% of the European genetic variants (based on the 1000 Genomes 
data, release May 2011) and mainly misses the low frequency variants. Low and 
rare frequency variants are more likely to be population-specific (15), therefore 
even if they were included on the Immunochip they might be of only limited value. 
At the moment there is no sequence data available for north Indian populations 
and it is difficult to estimate how well the Immunochip performs in this population. 
Our transferability success rate is probably underestimated, while differences in 
haplotype frequencies and LD mean it is likely that the Immunochip covers the 
genetic variation in north Indians less well than in Europeans.
 India has been under-represented in genome-wide association studies and 
we are the first to report an association study on coeliac disease in north Indians and 
to establish the association of 13 loci in this population. The lack of replication of 
the remaining 13 European loci may be due to the limited power of our study, and/
or poor tagging properties of the causal variant of the tested SNPs in north Indians. 
However, it is also likely that some European loci will not confer risk for coeliac disease 
in north Indians. Despite the fact that our north Indian cohort was half the size of 
the Dutch cohort, the association signals at the ITGA4/UBE2E3, PLEK, TAGAP and 
ICOSLG loci were equal or stronger in the north Indians than those in the Dutch. This 
indicates that some regions may confer different risk burdens in different populations. 
 North Indians, although genetically close to Europeans, differ markedly in 
their allele frequencies from Europeans, which is partly reflected by a lesser degree 
of LD structure compared to Europeans (16). The different allele frequencies and 
lower extent of long-range LD in north Indians resulted in different association 
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signal localization, or allowed finer-scale mapping at some loci. For example, the 
IL2/IL21 locus consists of a large LD block of 315 kb that covers the majority of 
the 591 kb region with highly correlated markers. It contains four genes: two are 
interleukins, IL2 and IL21, one plays a role in spermatogenesis (ADAD1), and one 
is a transcript of unknown function (KIAA1109). Because of its very strong LD, this 
region has not been fine-mapped successfully using European samples. Our study 
shows that north Indians have a higher proportion of low frequency markers (MAF 
< 0.1) than the Dutch, which breaks down the LD structure. The association signal 
localizes in the small 21 kb LD block (from 123246319 bp to 123267319 bp) adjacent 
to the larger block covering the KIAA1109 gene and the top European associated 
SNP. A recent study (12) showed that there are two independent signals at this 
locus, with SNPs in LD with the top independent SNPs scattered throughout the 
region. We noted that neither of the two independent signals were mapping 
within the identified north Indian risk haplotypes. Although we narrowed down 
the association signal to the 21 kb block, it does not include a gene, which could 
suggest that the causal variant plays a regulatory role, and although the associated 
LD block is in the immediate proximity of KIAA1109, the variant may also impact the 
more distal interleukin genes. This possibility needs to be followed up, preferably by 
sequencing the region in the north Indians to identify all variants in LD with the top 
transferable SNP. Thus, although we were not able to pinpoint the likely causal gene 
in this region, we did succeed in narrowing down the association to a small genetic 
interval. Another successful example is the ETS1 locus, where the north Indian 
signal is limited to tightly clustered variants, suggesting that the causative variant 
resides within a small 21 kb genetic interval (from 127882690 bp to 127904148 bp). 
  Differently localized association signals could also indicate locus 
heterogeneity and different biological pathways underlying the disease aetiology. 
In our previous GWAS (10), in which we established an association at the 6q22.33 
locus, we suggested THEMIS as a plausible candidate gene. However, fine-mapping 
in the Europeans using Immunochip clearly points towards the neighbouring PTPRK 
gene, a protein tyrosine phosphatase, whereas the north Indian signal points 
towards THEMIS. Unless functional follow-up studies are conducted to confirm a 
gene’s causality, it will remain unclear which gene truly plays a role in the disease 
pathogenesis. Or, perhaps, a more complex mechanism including both genes may 
act at this locus. PTPRK and THEMIS are both attractive candidates to act in coeliac 
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disease pathogenesis: PTPRK, as a signalling molecule regulating a variety of cellular 
processes, including cell growth or differentiation, and the neighbouring THEMIS 
gene, which regulates positive and negative T-cell selection during thymocyte 
development. THEMIS is transcribed from the reverse strand and, in fact, both 
associations could still point to the same gene, for example, in the Europeans 
by affecting the transcription regulation and in the north Indians by affecting a 
regulatory mechanism within the gene or by altering the gene structure. This 
requires follow-up studies for further elucidation.
 We found suggestive evidence of positive selection pressure acting on four 
of the 26 coeliac disease loci: IL18RAP (rs7559479), CCR1/5 (rs13098911), SH2B3 
(rs653178) and PLEK (rs17035378) (Table S4) (17-19). We found the strongest 
selection signal (Fst = 0.251) at the SH2B3 locus, which was previously suggested to 
play a role in bacterial infection (17). The SH2B3 locus does not replicate in our north 
Indian cohort, possibly because selection pressure led to a significant decrease in 
the risk allele frequency of the index SNP (rs653178) in north Indians (11% versus 
47% in the Dutch). 
 We have replicated coeliac disease associations in a north Indian population 
and also localized and fine-mapped the association signals. However, signatures 
of positive selection pressure acting on 15% of the loci and our partial replication 
success could indicate that there are different mechanisms of coeliac disease 
pathogenesis in the two populations. The modest size of our cohort requires our 
results to be followed-up in larger samples. We recommend that in any future 
replication studies in north Indians or other non-Caucasian populations, both the 
European index SNPs, as well as the top variants from this study, should be tested 
to better distinguish the relevant signals. Furthermore, our studies should benefit 
greatly from the 1000 Genomes sequence information for north Indians. This 
data will allow us to collate information on all the variants that are in LD with the 
transferable markers identified in our study and to describe more precisely the LD 
structure and genetic boundaries of variants strongly correlated with associated 
SNPs. The key to effective fine-mapping is to perform dense genotyping that 
includes all the known markers present in the north Indians. The results could have 
an immediate impact by allowing us to refine the associated coeliac disease regions 
to precise genetic intervals which include the causal variants. 
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Where are we now in mapping genetic diseases?
There are around 7,000 monogenic disorders registered in the online 
Mendelian inheritance in man database (OMIM: http://omim.org/) but the causative 
gene has been identified for around only half of them. Many causal genes have been 
discovered using positional candidate mapping, i.e. by combining genetic mapping, 
such as linkage or homozygosity, with the candidate gene approach (1). In the field 
of complex diseases, huge progress was achieved when the first GWAS (genome-
wide association study) was performed in 2005, and since then several hundreds 
of common loci have been associated to many different complex traits (2). In my 
thesis I describe the identification of new variants for both monogenic and complex 
diseases, thereby touching upon a wide range of mapping tools currently in use and 
showing their limitations and drawbacks. I also touch on the future perspectives of 
genetics analysis tools and how they could be used in the patient care.
Linkage analysis and GWAS 
Linkage analysis is a powerful tool for mapping candidate regions for well-
defined monogenic disorders with a highly penetrant and clear inheritance pattern 
(3). However, some monogenic diseases can be expressed as complex phenotypes 
with low penetrance (e.g. familial neuroblastoma (4), or may be seen as sporadic 
cases due to de novo mutations (e.g. recessive autosomal microvillus inclusion 
disease, chapter 2 in this thesis); applying linkage analysis might then be less than 
ideal. Moreover, the statistical tools applied in linkage analysis require the effective 
dataset to have sufficient power, so that one large affected family or many smaller 
affected families pooled together are needed; locus heterogeneity can be a problem 
in the latter case if each family is linked to a different genomic location for disease risk. 
Microvillus inclusion disease (MIVD) is an autosomal recessive disorder 
that is presented in chapter 2. Although of high penetrance, its genetic analysis 
suffers from some of the above bottlenecks, including de novo mutations, allele 
heterogeneity, and a small number of families – since the disease is very rare and 
fewer than 30 cases have been described in the literature (OMIM: http://omim.
org/). Fortunately, we could map the gene for MIVD using homozygosity mapping, 
as one of the families was consanguineous. We found that the MYO5b gene was 
present in one of four large, homozygous regions (> 20 cM) and it became a very 
strong candidate since it harbored different pathogenic mutations in different 
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families. More evidence that this gene is the causative one was presented by 
another research group, who made the same discovery using this approach (5). 
Linkage analysis is also not the most appropriate tool for mapping complex 
diseases as these are highly heterogeneous, of low penetrance, and the causative 
variants are of rather moderate effect size (6, 7). To overcome this problem, model-
free linkage analysis is often used in families segregating for complex disorders. 
This approach was used in work on celiac disease, (“Exome sequencing in a family 
segregating for celiac disease”, chapter 4, this thesis). Candidate regions with non-
parametrical linkage were established. Although the family was fairly large (four 
generations), the linkage analysis could still suffer from non-Mendelian inheritance 
as the statistics for both analyses were not highly significant (non-parametrical 
linkage values (NPL) < 3).We therefore searched for potential mutations not only in 
the linkage regions but on an exome-wide scale. 
Impressive progress in the genetics of complex diseases has been 
achieved since 2005 when the first GWA study was performed. Many replication 
studies followed and some of the GWAS results proved to be replicable in other 
populations while some were not, indicating heterogeneity plays a role in complex 
genetic diseases. In chapter 6, “Cross-ethnic replication and fine-mapping of celiac 
disease loci in a north Indian population”, we described a “locus-wide replication” 
(called transferability) in an Indian cohort of 26 independent GWAS signals for 
celiac disease mapped in Europeans. Due to differences in the allele frequencies 
of variants, as a result of differences in linkage disequilibrium (LD) among the two 
populations, the direct replication of single variants might not succeed (8). We 
therefore used all the single nucleotide polymorphisms (SNPs) from the 26 loci 
to investigate their association to celiac disease in the Indian population. In this 
way we managed to replicate around 50% of the findings in Europeans. GWAS for 
autoimmune diseases such as inflammatory bowel disorder (IBD) and celiac disease 
have mapped around 100 common loci, with the majority of these being involved 
in immune-related pathways (9). The same loci have been associated to many 
autoimmune disorders, making it clear that there is a common genetic background 
for such disorders and that the final phenotype is shaped by environmental factors 
as well as private variants (both common and rare ones) (10). Following on from 
this work, cross-replication studies were performed where a gene associated to 
one disease was investigated for another similar disorder. In chapter 5 I described 
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the cross-replication of a functional variant in the IL12b gene for ulcerative colitis. 
This was a direct replication of a known functional variant that had previously been 
correlated with other autoimmune (complex) diseases. 
Overall, we are not able to map monogenic mutations of more complex 
inheritance by using candidate positional studies, although for complex genetic 
diseases, we were able to correlate an impressive number of loci to a disease. 
However, these loci still explain only a small part of the heritability because they 
only confer a low risk. In conclusion, monogenic as well as complex diseases are 
still facing difficult times and new technologies are required to make the discovery 
rate of causative genes more effective. One of the rapidly evolving, high-throughput 
tools is next-generation sequencing (NGS), which offers the possibility of discovering 
a variety of risk variants for both monogenic and complex diseases.
Next-generation sequencing: tool for mapping monogenic and complex genetics
NGS is a high-throughput technique which enables researchers to perform 
a parallel, fast and effective sequencing of the genome of any individual (11). 
This method is not biased to any restricted pool of variations and by appropriate 
data analysis we are able to investigate all the variants together: rare, moderate 
and common ones (12). NGS enables us to skip the traditional “mapping step” by 
going directly to interpreting the candidate variants (13), allowing for unbiased 
investigation of variants regardless of the gene’s function. This is done by applying 
different prioritization tools in order to distinguish natural, non-pathogenic variants 
from mutations in the candidate region or genome-wide (14).
For each type of disease (monogenic or complex), the most important step 
is to define the character of variants to be prioritized. The easiest to identify are 
homozygous mutations of very low frequency, thus monogenic recessive diseases 
are the easiest to analyze. The so-called “double-hit” approach requires only a 
single individual with a recessive disease and carrying a homozygous, damaging 
mutation that is not present (or with very low minor allele frequency (MAF)) in 
ethnically matched controls or public datasets, such as the 1000 Genomes project 
(Figure 1 and table 1). This approach was used to map rare mutations associated to 
familial hypolipidemia (15). By applying a double-hit approach to a consanguineous 
family in our MVID study (“Functional characterization of mutations in the myosin 
gene associated with microvillus inclusion disease”, chapter 2, this thesis) we could 
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Table 1 Methods that could be used in the future to diagnose monogenic and complex diseases, 
depending on the hypothesis adopted and showing the advantages and disadvantages. 
Hypothesis Method Advantages Disadvantages




One patient, one experi-
ment 
Private set of ethnically matched 
controls




One patient, one experi-
ment Homozygosity mapping required
Mutation is of high pen-
etrance Linkage + NGS
No selection bias,2nd pa-
tient sequenced to reduce 
number of variants
Linkage mapping is required and 
co-segregation of many variants
Multiple mutation(s) in the 





Heterogeneity (if present). In 
case-control design need for large 
ethnically matched sample size
Mutation in gene which 





Biased approach, other additional 
data needed e.g. gene expression
Mutation present only in 
offspring
De novo (NGS 
only)
Detectable 
Depends very much on the qual-
ity of the data
have skipped the homozygosity mapping and performed only one experiment. In 
the case of consanguineous families, both methods should be successful, however 
NGS means such a study is more efficient and simply faster.
In the case of dominant and compound heterozygous mutations, the 
interpretation of NGS results can be more difficult. This is because a single genome 
is estimated to carry around 530-610 potentially damaging, loss-of-function 
variants (in-frame and out-of-frame indels, premature stop codons, and damaging 
splice sites), with the majority being heterozygous. About 100 of these variants 
will completely inactivate genes, whereas the rest will influence gene expression 
to different degrees (16, 17). In chapter 3, this thesis (“True autosomal dominant 
inheritance of FMF caused by a mutation in exon 8 of the MEFV gene”) we presented 
a family segregating for dominant autosomal disease. After applying filtering steps 
excluding all known, synonymous variants predicted to be bening we were still left 
with 125 variants for further consideration and only after applying the knowledge 
about the disease (candidate approach) we were able to narrow down our analysis 
to one potentially causative variant. In chapter 4, this thesis (“Exome sequencing in 
a family segregating for celiac disease”), I described a large family segregating for 
celiac disease in a dominant-like matter. Although we performed exome sequencing, 
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Figure 1 Presenting three steps that could lead to personalized therapy. 1. An interview with the 
doctor where a family history is recorded and inheritance is established. 2. The clinical molecular 
geneticist will choose the most appropriate method for diagnosis. 3. Based on the individual genetic 
risk, the therapy will be adjusted. 
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we were not able to identify a causative mutation. One of the reasons might be 
that we used a too stringent filtering as we only focused on nonsense variants and 
we could have overlooked the mutation since stop variants only make up a small 
proportion of the loss-of-function variants. This study was a good example to show 
that by defining filtering criteria, it is possible to (inadvertently) introduce bias. The 
best way to solve this problem would be to evaluate each type of sequenced variant 
(SV) separately using statistical estimation. This can be done by using “weighted” 
methods, where each of the variants is weighted based on its properties (MAF, 
damaging score, etc.), and p values are given as a measure of the association to the 
disease. A huge advantage of these methods is that they also correct for the size 
of the gene, so that large genes with many SVs do not introduce false-positive hits. 
By using this approach combined with a filtering-based method, Ionita-Lanz et al. were 
able to map known genes for three monogenic diseases using simulated data (18). 
For complex diseases, NGS gives the possibility of simultaneously 
investigating a wide range of rare variations of moderate and strong effect size, 
which is not possible using GWAS (2, 19). A case-control set-up has the power 
to detect causative variants, both common and rare, aggregating in the same 
gene (Figure 1 and table 1). However, as in GWAS, the sample size is crucial and 
large case-control studies need to be analyzed in order to pinpoint a true signal. 
In a study by Surolia et al. (20) the authors analyzed data from an inefficient sized 
cohort of 923 cases, suffering from different inflammatory disorders (such as 
type 1 diabetes, rheumatoid arthritis, ulcerative colitis, and others) and 
648 controls. They reported rare variants in the SIAE gene as being associated to 
the autoimmunity. A replication study performed by a different consortium used 
a much larger case-control group of 66,924 individuals in total and proved Surolia 
et al.’s finding to be a false-positive (21). Many statistical techniques have been 
described for associating rare variants in a case-control design to the disease under 
study. The techniques all show a different performance so it is important to choose 
the most suitable one in order to minimize false-positive associations (22). 
Another possible approach to identifying rare or common variants is to 
perform a single marker test, as shown by Rivas et al. (23). However, the single 
marker test is, by design, not able to pick up the combined effect of variants on 
a population level or to detect such a concentration of causative variants in cases 
where the collapsing (burden) test needs to be used. In the work of Nejentsev et 
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al. (24), SVs were found to be associated to type 1 diabetes (T1D) with the use of 
Fisher’s exact test, which directly compares the number of filtered SVs in cases versus 
controls. However, this and similar methods do not correct for the effect size (odds 
ratio, OR) of the variants or the MAF, which might be crucial when searching for rare, 
moderate and common variants in one experiment. Many “weighted analyses” have 
recently been developed in order to implicate different covariates (25, 26). Using 
the C-α test (27) that investigates the enrichment of variants by taking into account 
the direction of the effect, Torgerson et al. (28) were able to correlate rare variants 
in four out of nine candidate genes for asthma susceptibility. Overall, the statistical 
techniques applied to investigate rare variants for complex diseases in NGS data 
represent a new field of statistical genetics, which still needs to be improved (29). 
In chapter 6, this thesis (“Cross-ethnic replication and fine-mapping of celiac disease 
loci in a north Indian population”), we have described the follow-up of a GWAS 
analysis based on the ImmunoChip. By using a haplotype sharing approach, we were 
able to narrow down the regions and pinpoint the risk haplotypes in the IL2-IL21 
locus. If I could perform a follow-up study, I would select individuals carrying the risk 
haplotypes (cases) or the non-risk haplotypes (controls). Then I would use NGS to 
target the entire IL2-IL21 locus rather than exome sequencing, followed by one of 
the weighted analyses described above, so that as many variables as possible would 
be taken into account and allow investigation of many different variants in one 
experiment. In chapter 5, this thesis (“Functional polymorphism in IL12B promoter 
site is associated with ulcerative colitis”) I describe an investigation into the coding 
part of IL12b for additional functional variants associated to ulcerative colitis (UC). 
We did this by traditional Sanger sequencing on some 400 chromosomes. As we did 
not find any additional variants correlated to ulcerative colitis, the next step would 
be to sequence the entire IL12b locus and, by applying weighted analysis, compare 
a large group of cases versus controls for the enrichment of functional variants, 
including non-coding variants, in the entire IL12b locus.
Regardless of the experimental set-up, the analysis of NGS data for 
monogenic or complex diseases presents the problem of how to filter the bulk of 
non-causative SVs out of the datasets. The most powerful selection step is filtering 
against private or publicly available NGS datasets. By comparing cases to a carefully 
matched set of controls, it is possible to reduce the amount of data by about 
95%, leaving fewer than 500 variants to be prioritized further (13). Analysis of five 
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European populations by Zaboli et al. (30) showed that 63% of SVs from NGS data 
were common for all cohorts, while 19% were present only in one of five, i.e. were 
private, specific variants. Moreover, 62% of novel SNPs (i.e. those not reported 
before) were highly population-specific (30). In this case, using data only from the 
1000 Genomes project is not sufficient and other, more population-specific datasets 
need to be created or consulted. In study presented in chapter 3, this thesis (“True 
autosomal dominant inheritance of FMF caused by a mutation in exon 8 of the 
MEFV gene”), I mapped a new mutation for a monogenic, autosomal dominant 
disease in exome data from two related, affected individuals. After excluding all the 
private and homozygous variants and filtering the data against the dbSNP database 
and the 1000 Genomes project, I was able to narrow down the number of variants 
from 2,225 to 159 (shared by both individuals). It is possible that by using data from 
ethnically better matched controls, I could reduce this number even further. Exome 
sequencing of 200 unrelated Danish individuals was sufficient to call variants with 
a MAF > 0.02 with a 5% false-negative rate (31), which implies that more samples 
are required for variants with even lower MAF. Recently, the genomes of 250 Dutch 
trios (parents+child) were sequenced in the Genome of the Netherlands project 
(GoNL; www.nlgenome.nl) with 12x mean coverage and the data is currently being 
analyzed. This large, population-specific dataset includes approximately 20 trios per 
province and will be a source for MAF estimations of rare variants that are exclusive 
for the Dutch population. Moreover, the trio design allows for a highly reliable 
validation of variants using identical-by-descent analysis. 
Although NGS is a powerful tool to identify new genes, the success rate still 
depends on the enrichment kit for the exome sequencing. Some genomic loci are 
not well covered by exome enrichments due either to their high guanine-cytosine 
(GC) content or simply because they are not included in the enrichment method 
(13, 32). For example, a causative mutation in SMOC2 gene was found using the 
traditional positional-candidate approach, but it was missed by whole exome 
sequencing as the region was not well enriched (33). A group from Nijmegen did 
not identify the mutations for Kabuki syndrome (13), whereas Ng et al., investigating 
the same disease, were able to find causative variants in the MLL2 gene by using 
a different enrichment kit (34). In the study presented in chapter 4, this thesis 
(“Exome sequencing in a family segregating for celiac disease”) we used one of 
the commercially available kits for exome enrichment. We may have missed the 
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mutation as the gene was not captured by our kit and it is always worth considering 
this possibility before deciding on between a whole-genome or whole-exome 
sequencing approach. 
Overall, I think that applying NGS to much of my work would shorten the 
time taken to discover new mutations (“Functional characterization of mutations 
in the myosin Vb gene associated with microvillus inclusion disease”, chapter 2, 
this thesis). If we could use NGS in the work presented in chapter 5, this thesis 
(“Functional polymorphism in IL12B promoter site is associated with ulcerative 
colitis”) we would investigate the entire IL12b locus, including all the non-coding 
sequences, instead of focusing only on exons of the IL12b gene. NGS would be also 
my choice for continuing the fine-mapping of IL2-IL21 (“Cross-ethnic replication and 
fine-mapping of celiac disease loci in a north Indian population”, chapter 6, this 
thesis).
Prospective for NGS and genetics mapping: the personal genome 
NGS is a powerful tool and, when properly applied, it can reduce the 
diagnosis time to around 9 weeks. Although it is still relatively expensive (whole 
genome sequencing costs around $15,000, whereas exome sequencing is around 
$3,000), the costs are dropping fast and more diagnostic centers are starting to 
use this technology for patient care (35). In 2008 NIH’s Undiagnosed Disease 
Program was begun as a diagnostic program for rare genetic diseases and since then 
39 diseases have been diagnosed, of which only three could be resolved with NGS 
(exome sequencing) (35). This number will soon increase and more diseases will be 
automatically submitted for diagnosis with NGS. In order to use NGS as a general 
tool for diagnosis, some bottlenecks still need to be resolved, e.g. the storage of the 
huge amount of data generated is expensive, and general, well-established diagnosis 
pipelines for different diseases must be set-up (36, 37). In spite of these problems, 
some studies have already been published demonstrating the effectiveness and 
huge potential of NGS in diagnosis.
Unknown etiology of the disease 
 Diagnosing unknown disorders using NGS is gene discovery and overlaps 
with fundamental research. To solve the cause of the disease we can apply many 
combinations of tools commonly used in research with NGS (36). The strategy 
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will depend on the disorder and resources available. In Figure 1, I present the 
possibilities for various sets of diagnostic tools to discover the etiology of different 
genetic disorders. 
Fast and efficient screening 
 NGS offers the possibility to sequence many samples in parallel by using 
bar-coding and pooling, which can make diagnosis faster and cheaper. To pool many 
patients and still get good coverage, genomic enrichments are restricted to certain 
genes that have already been implicated in the disease or in diseases with similar 
phenotypes. In the work of Corrales et al., 40 patients were pooled and sequenced 
to determine the causative gene (VWF) for Von Willebrand disease, with a discovery 
rate of 27.5% (the remaining ‘results’ were due to indels and as the group used 
single read sequencing, they could not easily pinpoint these) (38). They estimated 
that, for around 10 kb of sequence, they were able to pool 350 individuals in one 
experiment and still have sufficient coverage to discover mutations. 
Re-diagnosis of unresolved cases
 By using exome sequencing Leidenroth et al. were able to adjust the 
diagnosis of patients with facioscapulohumeral muscular dystrophy (FSHD) (39). 
They did not confirm the mutations in the known causative gene for FSHD, but found 
well-established risk mutations in the CAPN3 gene, indicating a case of limb-girdle 
muscular dystrophy type 2A rather than FSHD. A similar case was described by Choi 
et al. where a child from consanguineous marriage was diagnosed with Barrett’s 
syndrome (40). However, exome sequencing identified a homozygous mutation in 
the SLC26A3 gene, associated to other autosomal, congenital chloride diarrhea gene 
disease, but not in any known genes for Barrett’s. NGS in nine additional Barrett’s 
syndrome patients, for whom no mutation had been found in known genes, revealed 
damaging mutations in SLC26A3 for five of them. These two examples clearly show 
the power of using a hypothesis-free NGS method to diagnose patients accurately.
Pharmacogenomics 
 By performing GWAS scientists were able to adjust drug therapies in, for 
example, cardiovascular and infectious diseases, based on the common variants 
discovered. NGS also offers the opportunity of investigating rare variants which 
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might be more specific for the disease and, based on their genotypes, the treatments 
could be adjusted more precisely (Figure 1). Most attention is being given to cancer 
and cardiovascular and immune disorders. Re-sequencing studies have already 
started that will include many individuals in order to find specific biomarkers which 
will lead to gene-specific therapies. Recently 3,000 individuals with cancer were 
enrolled in the USA to undergo exome sequencing of different types of tumors to 
establish cancer-specific biomarkers (41), while in the large-scale Tumor Sequencing 
Project (TSP), 632 cancer related genes were sequenced in 188 pairs of tumor and 
normal tissues in order to find new somatic mutations for lung adenocarcinoma 
(42). Many of the mutations discovered were found in suppressor genes known to 
be involved in other types of cancers. These and similar studies will, in the future, 
allow the type of chemotherapy to be determined by the mutated gene. 
In conclusion, we are approaching very exciting times in the field of genetics. 
New technologies will allow for personalized treatment that should lead to better 
patient care, although there are still several ethical and practical issues that need 
to be solved (43). In spite of these, we are now entering a new era of personalized 
genomic medicine.
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 Ieder van ons is een uniek individu en wij allen verschillen in uiterlijk, 
persoonlijkheid, of talenten; sommigen van ons worden vaker ziek en sommigen 
kunnen harder rennen dan anderen. Er zijn twee belangrijke groepen van factoren die 
leiden tot de ontwikkeling van deze individuele kenmerken: (1) exogene factoren, dat 
wil zeggen alle milieu- en andere externe factoren, zoals luchtvervuiling, infecties, of 
het niveau van het onderwijs, en (2) erfelijke factoren, dat wil zeggen alle informatie 
opgeslagen in ons DNA. Het verschil in betrokkenheid van elk van deze factoren 
beïnvloed de aard van de eigenschap (een fenotypisch kenmerk, gerelateerd aan 
ziekte of niet-ziekte gerelateerde factoren). Bijvoorbeeld het vermogen om de tong 
op te rollen is een sterk erfelijke eigenschap die dus afhangt van de genetische 
informatie in je DNA en niet direct door exogene factoren. Dit soort kenmerken 
worden monogene eigenschappen genoemd, omdat er slechts een gen is die de 
eigenschap bepaald en de invloed van exogene factoren zeer beperkt is. Een ander 
voorbeeld is de body mass index (BMI), die wordt bepaald door meerdere genen 
overgeërfd van je ouders (bijvoorbeeld de genen die de stofwisseling reguleren) en 
door de omgeving en levensstijl (bijvoorbeeld dieet, lichaamsbeweging). Dit soort 
eigenschappen worden complexe eigenschappen genoemd, omdat ze beïnvloedt 
worden door tal van genetische en omgevingsfactoren.
 Elke omgeving- of genetische verandering kan invloed hebben op 
deze eigenschappen en kan leiden tot ziekte. Om ziekten te voorkomen 
en te genezen heeft de medische wetenschap veel energie gestoken in 
het ontdekken en het uitleggen van de bijdragen van zowel omgeving- als 
genetische factoren voor de menselijke gezondheid en ziekten. Het belangrijkste 
doel van epidemiologische studies is om veranderingen in de omgeving aan 
verschillende menselijke eigenschappen te correleren, terwijl de medische 
genetische studies focussen op het onderzoeken van afwijkingen in ons DNA bij 
verschillende complexe  (bv.  kanker, diabetes type 1, coeliakie) en monogene 
aandoeningen (zoals hemofilie uit te leggen, de ziekte van Huntington). 
 In mijn proefschrift presenteer ik een breed scala aan technieken die vaak 
gebruikt worden in huidig medisch genetisch onderzoek naar genen en mutaties 
betrokken bij verschillende ziekten met verschillende genetische achtergronden. 
In hoofdstuk 1 introduceer ik de twee belangrijkste groepen van genetische 
aandoeningen: monogene en complexe aandoeningen. Ik presenteer de kenmerken 
van de genetische componenten die ten grondslag liggen aan beide groepen van 
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genetische ziekten, de verschillen tussen hen, en toon de betrokkenheid aan van 
genetische en omgevingsfactoren in de ontwikkeling van elke ziekte. Ik leg ook 
de meest gebruikte methoden uit om de oorzakelijke genen voor beide groepen 
van ziekten in kaart te brengen, en ik benoem hun belangrijkste knelpunten. 
 In de hoofdstukken 2 en 3 presenteer ik twee monogene ziekten en twee 
verschillende toegepaste technieken om hun causale genen te achterhalen. In 
hoofdstuk 2 wordt een geval besproken van recessieve microvillus inclusieziekte in 
een consanguine familie (de ouders van de getroffen kinderen waren eerstegraads 
neef en nicht). Bij deze ziekte wordt de opname van voedingsstoffen uit de dunne 
darm bij een pasgeborene ernstig verstoord. De oorzakelijke mutatie in het gen Myo5b 
is in kaart gebracht met behulp van de positionele kandidaatgen aanpak: kennis 
over eiwit-expressie bij patiënten in combinatie met hypothesevrije genetische 
mapping stelde ons in staat om dit oorzakelijke gen te vinden. Hoofdstuk 3 beschrijft 
een dominante monogene ziekte, familiale mediterrane koorts, overervend in een 
familie over drie generaties. Deze ziekte is een immunologische aandoening die 
wordt gekenmerkt door periodes van hoge koorts en andere symptomen, zoals 
huiduitslag. Deze studie toonde de kracht van een vrij nieuwe, hypothesevrije, 
next-generation sequencing methode, waarbij het gehele exoom van een individu 
werd gesequenced en stapsgewijze filtering werd toegepast op meer dan 20.000 
varianten om een oorzakelijke mutatie te identificeren in exon 8 van het MEFV gen. 
 Hoofdstukken 4, 5 en 6 beschrijven twee complexe ziekten waarbij de 
dunne darm is aangedaan: coeliakie, waarbij gluten een sterke immuunreactie in 
de dunne darm veroorzaakt (hoofdstukken 4 en 6) en colitis ulcerosa, een immuun-
gerelateerde ziekte van de dunne darm waarbij de omgevingsfactor nog niet bekend 
is, maar die ligt in een overmatige immuunreactie op de darmflora. Hoofdstuk 4 
beschrijft een grote familie (vier generaties) van Nederlandse afkomst waarin 
coeliakie overerft. De prevalentie van de ziekte is zeer hoog in deze familie en maar 
liefst 40% van de nakomelingen in de eerste generatie in aangedaan, wat kenmerkend 
is voor monogene dominante ziekten. We hebben daarom gezocht naar een sterke 
mutatie in het hele exoom in next-generation sequence data. Hoewel we niet in 
staat waren om de oorzakelijke mutatie te vinden, was deze studie erg belangrijk 
omdat het de complexiteit en de moeilijkheden aantoont van het beperken van 
een vermoedelijke genetische regio om een  oorzakelijke variant te identificeren in 
families waarin een complexe aandoening met een Mendeliaans patroon overerft. 
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 Hoofdstukken 5 en 6 illustreren verschillende benaderingen van replicatie 
voor het werk beschreven zoals in hoofdstuk 4. In hoofdstuk 5 wordt een “ziekte-
kruisende” benadering toegepast, waarbij we de associatie van een functionele 
variant in de promotor regio van IL12B met colitis ulcerosa gerepliceerd hebben. 
Dezelfde variant was al in verband gebracht met andere immuun gerelateerde ziekten. 
 In hoofdstuk 6 wordt een “etniciteit-kruisende” replicatie studie 
beschreven waarin varianten geassocieerd met coeliakie in een Nederlands 
cohort werden onderzocht in een ander cohort van een andere etnische 
afkomst (Noord-Indiërs). Deze studie toonde de kracht van het gebruik van 
locus replicatie in plaats van enkele variant replicatie, omdat verschillen in 
“linkage disequilibium” tussen populaties foutnegatieve resultaten kunnen 
introduceren. Met behulp van een haplotype-sharing methode hebben we 
het associatie gebied van het IL2-IL21 locus teruggebracht met een factor 30, 
waardoor fine-mapping van de oorzakelijke variant beter mogelijk is gemaakt. 
 In hoofdstuk 7 bespreek ik de behaalde resultaten in de humane genetische 
studies van monogene en complexe ziekte, en presenteer ik een toekomstperspectief 
op het in kaart brengen van genen met de focus op next-generation sequencing. 
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Each of us is a unique individual and we all differ in looks, personality, 
or talents; some of us get sick more often or can run faster than others. There 
are two main groups of factors that lead to the development of these individual 
characteristics: (1) exogenous factors,  i.e. all environmental and other external 
factors, such as air pollution, infections, and level of education, and (2) inherited 
factors, i.e. all the information carried in our DNA. The differential involvement of 
any of these two types of factors influences the character of the trait (a trait is a 
phenotypic characteristic, related to disease or non-disease factors), for example, 
the ability to roll your tongue is a strongly inherited trait and depends on the genetic 
information in your DNA, so exogenous factors cannot influence it directly. These 
kinds of traits are called monogenic traits, because only one gene is controlling it 
and the influence of exogenous factors is very limited. Another example is your 
body mass index (BMI), which is defined by multiple genes inherited from your 
parents (e.g. the genes controlling metabolism) and by the environment you live 
in (e.g. diet, exercise). These kinds of traits are called complex traits as they are 
influenced by many genetic and environmental factors. 
Any environmental or genetic change can affect such traits and may lead to 
disease. To prevent and cure diseases, medical science is putting much effort into 
discovering and explaining the contributions from both environmental and genetic 
factors to human health and diseases. The main goal of epidemiological studies is 
to correlate changes in environment to different human traits, whereas medical 
genetic studies focus on investigating aberrations in our DNA to explain different 
complex (e.g. cancer, type 1 diabetes, celiac disease) and monogenic disorders (e.g. 
hemophilia, Huntington’s disease). 
In my thesis I present a wide spectrum of tools commonly used in current 
medical genetic studies to identify the genes and mutations that lead to diseases 
governed by different types of genetic architecture.
In chapter 1, I introduce the two main groups of genetic disorders: 
monogenic and complex disorders. I present the characteristics of genetic 
components underlying both groups of genetic diseases, the differences between 
them, and have illustrated the involvement of genetic and environmental factors 
in the development of each disease.  I also explain the most common methods 
used to map the causative genes for both groups of diseases, and I assess the main 
bottlenecks affecting these methods. 
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In chapters 2 and 3, I present two monogenic diseases and two different 
tools used to discover their causal genes. Chapter 2 presents a case of recessive 
microvillus inclusion disease in a consanguineous family (the parents of the affected 
child were first-degree cousins), in which uptake of nutrition from the small 
intestine in a newborn was disturbed. The causative mutation in the gene Myo5b 
was mapped using the positional-candidate approach: knowledge about protein 
expression in patients combined with hypothesis-free genetic mapping enabled 
us to find this causative gene. Chapter 3 presents a dominant monogenic disease, 
Familial Mediterranean Fever, segregating in a family over three generations. This 
disease is an immunological disorder characterized by periods of high fever and 
other symptoms, such as skin rash. This study showed the power of a fairly new, 
hypothesis-free, next-generation sequencing method, in which the entire exome 
of an individual was sequenced and step-wise filtering was applied to more than 
20,000 variants in order to identify one causative mutation in exon 8 of the MEFV 
gene.
Chapters 4, 5 and 6 present two complex diseases that affect the small 
intestine: celiac disease, in which gluten triggers a strong immune response in the 
small intestine (chapters 4 and 6) and ulcerative colitis, an immune-related disease 
of the small intestine for which the environmental factor is still unknown, but which 
may lie in an excessive immune response to the intestinal microflora. Chapter 4 
describes a large family (four generations) of Dutch origin segregating for celiac 
disease. The prevalence of the disease is very high and affects as many as 40% of 
the offspring in the first generation, which is characteristic for monogenic dominant 
diseases. We therefore looked for a strong mutation in the exome-wide next-
generation sequence data. Although we were not able to find the causal mutation, 
this study was very important since it demonstrated the complexity and difficulties 
of narrowing down a suspected genetic region to a causative variant in families 
segregating for complex disorders with a Mendelian-like inheritance pattern. 
Chapters 5 and 6 illustrate different replication approaches for the work 
described in chapter 4. In chapter 5 we applied a cross-disease approach, in which 
we replicated the association of a functional variant in the promoter site of IL12b 
with ulcerative colitis. The same variant had already been associated with other 
immune-related diseases.
 Chapter 6 describes a cross-ethnic replication study in which variants 
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associated to celiac disease in a Dutch cohort were examined in another cohort 
of different ethnic origin (North Indians). Here we showed the power of using 
locus replication rather than single variant replication, since differences in linkage 
disequilibrium between populations might introduce false-negative results. Using 
a haplotype-sharing method, we narrowed down the association region at the IL2-
IL21 locus by a factor of 30 , thereby making fine-mapping to the causal variant 
more feasible.
In Chapter 7 I discuss the achievements in human genetic studies of 
monogenic and complex disease, and present a future perspective on gene mapping 
with much of the focus on next-generation sequencing. 
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Każdy z nas jest inny. Różnimy się wyglądem, charakterem, talentami. 
Tak też niektórzy z nas chorują częściej niż inni, a jeszcze inni szybciej biegają, itp. 
Można wyróżnić dwie główne grupy czynników, które wpływają na każdą cechę. 
Pierwszą stanowią czynniki egzogenne, czyli środowiskowe np. zanieczyszczenie 
powietrza, przebyte infekcje czy edukacja. Druga grupa to czynniki dziedziczne, 
czyli cała informacja zawarta w naszym DNA. Czynniki obu grup mogą mieć różny 
udział w formowaniu cech, dlatego też cechy dzielimy na: cechy determinowane 
jednogenowo, czyli silnie dziedziczne, gdzie czynniki środowiskowe nie mają 
wpływu na ich kształtowanie lub wpływ ten jest bardzo ograniczony (np. zdolność 
układania języka w rurkę). Z drugiej strony mamy cechy złożone (wieloczynnikowe), 
gdzie zarówno czynniki środowiskowe, jak i czynniki dziedziczne odgrywają znaczną 
role. Na przykład współczynnik masy ciała (z ang. BMI, body mass index) jest cechą 
w części dziedziczną (geny odpowiedzialne za metabolizm organizmu), a w części 
kształtowaną przez czynniki środowiskowe (dieta, ruch i regularne ćwiczenia).
Każda zmiana w obrębie czynników środowiskowych albo dziedzicznych 
może prowadzić do zmiany cechy i w konsekwencji do choroby i spadku komfortu 
życia. Aby zapobiegać i leczyć wywołane w ten sposób choroby, niezbędne jest 
badanie wpływu czynników dziedzicznych i środowiskowych na nasze zdrowie. 
Wyodrebniamy dwie nauki: epidemiologię, która bada wpływ czynników 
egzogennych oraz genetykę medycznę badającą wpływ czynników dziedzicznych 
(zmian w DNA, czyli mutacji) na choroby złożone (np. nowotwory złośliwe, cukrzycę 
typu I, celiakię) i choroby jednogenowe (np. hemofilię, chorobę  Huntingtona).
Niniejsza praca doktorska prezentuje szerokie spektrum metod używanych 
w genetyce medycznej w celu identyfikacji czynników dziedzicznych, tzw. szukanie 
genów kandydatow, powodujących choroby jednogenowe i zlozone
W rozdziale 1. opisuję dwa typy chorób: złożone i jednogenowe 
z uwzględnieniem podstawowych różnic, zarówno w czynnikach genetycznych, jak 
i w ich odmiennym współdziałaniu z czynnikami środowiskowymi. W dalszej części 
rozdziału 1. ilustruję najczęściej używane techniki służące do poznania czynników 
dziedzicznych, które powodują daną jednostkę chorobową (mutacje w DNA) 
oraz przedstawiam najczęstsze przyczyny niepowodzenia metod.
W rozdziałach 2. i 3. przedstawam dwie choroby jednogenowe i dwie 
różne metody użyte w celu zidentyfikowania mutacji w genie kandydacie. 
W rozdziale 2. opisuję wrodzoną, autosomalną, recesywną atrofię mikrokosmków 
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(z ang. microvillus inclusion disease, MVID) zdiagnozowaną u dziecka pochodzącego 
z małżeństwa kuzynów pierwszego stopnia. U chorych obserwuje się zaburzone 
pobieranie pokarmu z jelita cienkiego. Mutacja w genie Myo5b została 
zidentyfikowana metodami przeszukiwania genomu oraz wyznaczaniu genu 
kandydata (z ang. positional-candidate cloning). Dzięki tym metodom byłam w stanie 
zidentyfikować region w genomie, gdzie prawdopodobieństwo znalezienia mutacji 
jest większe, a dodatkowa wiedza na temat ekspresji białek w tkance pacjenta 
pozwoliła mi na wskazanie jednego genu kandydata w tym regionie. W rozdziale 
3. przedstawiłam autosomalną, dominującą chorobę wrodzoną zwaną rodzinną 
gorączką śródziemnomorską zdiagnozowaną u członków trójgeneracyjnej rodziny. 
Choroba ta powoduje okresowe napady wysokiej gorączki i inne symptomy np. 
wysypkę na skórze. Praca ta ukazuje wielkie możliwości związane z nową techniką 
przeszukiwania genomu ludzkiego zwaną następną generacją sekwencjonowania 
(z ang. next generation sequencing, NGS). Cała informacja genetyczna kodująca 
białka została zsekwencjonowana w krótkim czasie i wszystkie zmiany w DNA 
pacjenta zostały odpowiednio opisane. W kolejnej fazie selekcyjnejjedna z 20,000 
opisanych zmian w egzonie 8 MEFV genu kandydata została zidentyfikowana jako 
powodująca chorobę.
W kolejnych rozdziałach opisałam dwie choroby złożone: celiakię, która 
spowodowana jest silną reakcją autoimmunologiczną w obecności glutenu w jelicie 
cienkim (rozdziały 4. i 6.) oraz ulcerozę , chorobę immunologiczną jelita cienkiego, 
dla której czynnik środowiskowy nie został poznany, chociaż może być silnie związany 
z mikroflorą jelita pacjenta.
W rozdziale 4. prezentuję czteropokoleniową rodzinę pochodzenia holenderskiego, 
w której celiakia występuje nadzwyczaj często i obejmuje 40% potomstwa 
z pierwszego pokolenia, co wskazuje na model dziedziczenia podobny do modelu 
dominującego, autosomalnego, w chorobach jednogenowych. Przyjmując ten 
model dziedziczenia, zastosowałam szybką i wydajną metodę NGS, gdzie w fazie 
selekcyjnej szukałam mutacji, która powodowałaby wysokie dziedziczenie choroby. 
Mimo, że nie udało mi się znaleźć mutacji, moja praca porusza ważną kwestię, 
ukazując szeroki wachlarz trudności związanych z przeszukiwaniem genomu 
w rodzinach cierpiących na złożone choroby o charakterze chorób jednogenowych.
W rozdziałach 5. i 6. przedstawiam różne metody używane w celach 
replikacji poprzednio uzyskanych wyników. W rozdziale 5. opisuję replikację 
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funkcjonalnej zmiany w IL12b genie kandydacie w ulcerozie. Ta sama funkcjonalna 
zmiana została juz poprzednio skorelowana z innymi immunologicznymi chorobami 
(tzw. replikacja międzychorobowa). Natomiast w rozdziale 6. zaprezentowałam 
replikację miedzypopulacyjną, gdzie zmiany w DNA skorelowane z celiakią 
w populacji holenderskiej zostały przetestowane w populacji hinduskiej z północy 
Indii. W pracy tej bardzo wyraźnie pokazałam wyższość replikacji wszystkich zmian 
w DNA z regionu kandydata, w przeciwieństwie do replikacji jednej, poprzednio 
najbardziej skorelowanej zmiany. Jest to ważne ze względu na różnice w wielkości 
regionów kandydatów, gdyż testując jedną zmianę, możemy otrzymać wynik 
fałszywie negatywny. W dalszej części rozdziału opisałam metodę wykorzystującą 
różne długości haplotypów w regionie kandydacie w celu jego zawężenia. Używając 
tej metody, zmniejszyłam region zawierający geny IL2-IL21 trzydziestokrotnie, dzięki 
czemu dalsze prace nad wskazaniem genu kandydata w tym regionie mogą być 
bardziej wydajne.
W rozdziale 7. opisuję i dyskutuję najnowsze osiągnięcia w identyfikacji 
genow kandydatow dla chorób jednogenowych i złożonych. Ostatecznie skupiam 
się na perspektywach, silnie odnosząc się do techniki, NGS, która moim zdaniem 
jest przyszłością genetyki klinicznej.
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to celebrate Christmas and New Year. Dear Robert, thank you for support during 
the difficult times. Richard, I would like to thank you for helping me with writing 
the letter of motivation to apply for the clinical medical geneticist position. Charles, 
I really appreciate that you pay attention to people and always remember people’s 
names. Ellen N., it was very nice to have conversations with you over lunch. Dear 
Brigit, thanks for explaining, over a delicious dinner, what the responsibilities of a 
clinical medical geneticist are. Dear Conny, thank you for some useful tips before 
visiting Joris in Belgium. Dear Marina, Edwin and Hayo, I would like to thank you for 
all your help with the administration, finances and computers. Dear Mentje, Ria and 
Joke, thank you for all the help you gave me with copying, sending and receiving 
documents. Bote, I really enjoyed your good spirit and optimism.
Special thanks to you, Hélène, for helping me with my thesis, and the submissions 
and appointments. Although you have so many things to deal with, you are always 
helpful and greet everyone with a huge smile. Justyn, dziękuję za wspaniałe lekcje 
reggeatonu. Wspaniale się bawiłam. Dear Helga and Annemieke, I enjoyed your dry, 
sarcastic and very intelligent sense of humor, just like mine :-). Dear Marlies, I really 
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enjoyed our after-work outings for fine food and wine. Dear Angela, I enjoyed our 
conversations about relationships and your delicious carbonara pasta. Dear Pieter 
(van der Vlies), I really appreciated your help with using a bolt cutter (betonschaar) 
and getting rid of stuff from my old house. Dear roommates: Aśka, Jihane, Paul, 
Dineke, Javier, Mats, Duco, Olga, Suzanne, Céline, and Cleo, thank you for a pleasant 
time and all the fine conversations. Dear Paul, I enjoyed talking to you, I really like 
your sense of humor. I wish you a lot of success in your future career. Duco, it was 
cool to hang out, drink beer, and eat sushi together. Dear Jantine, Michiel, I enjoyed 
talking to you over a beer. Rutger, you are a funny, good looking guy, thanks for that 
:-). It was a pleasure seeing you maturing ;). Karen T., I appreciated your “straight-
to-the-point” comments and good humor. I wish you all the best with opening a 
guesthouse.
Dear friends, co-workers and colleagues from genetics and other departments: 
Gerben, Peter A, Christine, Hans, Yvonne, Ludolf, Dasha, Yurike, Tjakko, Yunia, 
Omid, Eva, Anna P., Mariska, Bahram, Jelkje, Jan O., Rudolf, Nicole, Klaas, Rolf, Anna 
D., Elena, Fany, Bine, Maria, Kaushal, Mateusz, Anna F., it was very nice knowing 
you. Dear Jana and Masha, thank you for a delicious sushi and nice conversations. 
Masha, I wish you a lot of success and I am sure, one day, you will become a great 
Manga Creator. Dear Mathieu B., thank you very much for taking care of my rabbit, 
Kłapoucha. Good luck with your PhD study.
When I started my PhD in 2007, our Celiac group was rather small. Over these last 
five years, it was my pleasure to see how we grew. Dear Cisca, Aśka, Cleo, Isis, Gosia, 
Mathieu, Soesma, Barbara, Javier, Rodrigo, Vinod, Sebo, Senapati, Astrid, Patrick, 
Ania R., Maciek G., Sasha, and our old colleagues Monique, Ron, Martin W. and 
Marcel, thank you for all your input and comments during the Monday morning 
meetings. Dear super-Mathieu, I am still amazed by your energy. Thank you for 
always having time to go with me to the serum archive. Dear Soesma, I adore your 
children, especially your little girl. I will always remember your smile and high-
heeled shoes. Droga Małgorzato T., Gosiu, dziękuje za mile spędzone chwile. Dear 
Isis, I was honored to be your supervisor. I know you will become a great scientist 
one day. Dear Sasha, I appreciated your help in explaining the basics of population 
genetics to me and I enjoyed our trip in California.
Dear colleges in the bioinformatics unit, thank you for your input for my work. Dear 
Gerard te Merman and Lude, thank you for trying to explain some basic statistics 
to me. Dear Freerk, Morris, Alex, Patrick, Marc Jan, Harm-Jan, Roan, Peter, Juha 
and Jorris, thank you for helping me with the next-generation sequencing data, the 
annotation and writing some helpful scripts for me. Dear Jingyuan, I would like to 
thank you for helping me with R. Dear Freerk and Robert W., I really enjoyed the 
drum and bass parties with you.
Dear IBD team - dear Rinse, you are for sure the coolest MD I have ever met. Dear 
Noortje, thank you for our good time together, the dinners and going out. It was 
nice to stay at your parents’ home, since then I’ve been eating Clover honey for 
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breakfast. Karin, I think you are one of the most honest people I have ever known 
and because of that, it is so easy to communicate with you. Mitja, thank you for tons 
of movies, Balkan music and a fine time. Suzaaaanneeeee, pumpkin, you are just 
one of the best roommates I have ever had. 
My friends and buddies, it was a pleasure to share time with you, traveling, 
listening to music, drinking beer, relaxing, and discussing important as well as not 
so important issues :-).
Dimer, Albert, Remco, thank you for all the good fun, going out and time well spent 
in pubs :-). Marcinie, dziękuję Tobie za luncze, dowożone przez Aśkę. 
My “must know” couple, Magda and Christian, I enjoyed staying at your place in 
Rotterdam and crazy outings in Warsaw. 
Lotte and Ruud, thank you for being my buddies, especially at the beginning of my 
PhD. Dear Arnoud, thank you for helping me when you could.
Mats, my roommate, my friend, thank you for listening to all my troubles. I will 
always remember you and your passion for Indian food.
Monique, my friend, you are a very warm person. I enjoyed going with you to 
festivals and walking over the tidal mudflats (wadlopen). The Irish pub is where 
we should meet again. Dineke, isn’t it funny that me (the drama queen) and you 
(a person who always eats bananas for lunch and old Amsterdam cheese) became 
rather good friends? Whenever I need some sense in my life and a bit of structure I 
will contact you. It was a pleasure seeing you growing as a PI and now I hope to see 
you growing as a mother. Thank you for your friendship. 
Jihane, you are one of the sweetest girls I have ever met. Thank you for being next 
to me in the most difficult times as well as in the good ones. I hope to earn enough 
money to visit you one day in Lebanon. Kisses. 
Céline, although you do not pronounce “h”, I still adore you and your “frunchness”. 
I really look forward to going to France with you.
Giulia, the first time we spoke we had an argument and I thought you would not 
like me ... but you proved me wrong. I don’t know you that well, but I hope we 
will have a chance to become close friends as I really like you and appreciate you 
stubbornness :-).
Anno W., jak z nikim innym tylko z Tobą mogę rozmawiać o wszystkich sprawach 
sercowych I międzyludzkich. Wydaje mi się, że wiele nas łączy: charakter typu drama 
queen, wydawanie pieniędzy, podobne błędy życiowe i muzyka. Chyba dlatego 
dobrze się rozumiemy...i niech tak zostanie. Całuski. 
Anno Rybak, Rybaku, co jak co, ale Opener tylko z Tobą. Jesteś bardzo pozytywną 
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osobą. Początki moje w Groningen były pełne śmiechu. Lubimy się i czerpiemy z 
tego wiele radości i to jest takie miłe :-).
Anno R. i Norbercie, cieszę się że udalo nam się odnowić znajomość. Mile wspominam 
waszą wizytę w Groningen.
Luizo kochana moja, zostawiłam Cię w Polsce ale nigdy nie zapomniałam o Tobie. 
Cieszę się, że odnalazłaś swoje szczęście w roli matki, żony i naukowca. Obiektywnie 
patrzysz na moje sprawy i zawsze jesteś ze mną szczera, nigdy nie przestawaj tego 
robić. Dziękuję za miłość. Buziaki. 
Kochana Miraim, Aśko, na początku było dużo muzyki I dobrej zabawy. Później 
wspólne wieczorki I obiadki (pierogi, nadziewane kaczki i zupa z pieca). A potem to 
juz tylko bindole i Habibąki. Widzę wielki potencjał w lovebird, niech nam wzleci. 
Trzymam kciuki. Fajnie sie z Tobą rozmawia, od rzeczy i do rzeczy, podróżuje i wydaje 
pieniądze na ciuchy, kosmetyki i inne takie ... Wiem ze zawsze mogę na Ciebie liczyć 
i właśnie na tym polega przyjaźń. Dziękuje. 
My dear Valentin, although we met just at the end of my stay in Groningen, you 
have already become one of the most important people in my life. You make me 
happy and I wish for myself to have many beautiful moments with you. I hope we 
can spend some more time together soon. Kisses :*
Dziękuję swojej rodzinie. Drogi Krzyśku, dziękuję, że mogę na Ciebie liczyć w różnych 
sprawach życiowych: pielęgnacja ogrodu, pomoc w przeprowadzce, pomoc w 
zatrudnieniu i inne.
Kochana siostrzyczko, Zofio. Jestem z Ciebie bardzo dumna, że studiujesz, że masz 
pasję i że nieugięcie dążysz do swoich celów. Mam nadzieje, że się trochę nauczę od 
ciebie racjonalnego spojrzenia na świat i pewnego dystansu do życia. 
Moja droga mamo. Zawsze byłaś przy mnie i zawsze mnie wspierałaś. Dziękuję za 
miłość i pomoc, tą materialną :-), ale przede wszystkim mentalną. 
To all these fine people, I am grateful that I had the opportunity to meet you and I 
wish you all success and hope to see you again soon.
Thank you – Dank u wel – Dziękuje Wam!
Agata
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